CN1113862C - 芳基磺酰氨基异羟肟酸衍生物 - Google Patents
芳基磺酰氨基异羟肟酸衍生物 Download PDFInfo
- Publication number
- CN1113862C CN1113862C CN98802991A CN98802991A CN1113862C CN 1113862 C CN1113862 C CN 1113862C CN 98802991 A CN98802991 A CN 98802991A CN 98802991 A CN98802991 A CN 98802991A CN 1113862 C CN1113862 C CN 1113862C
- Authority
- CN
- China
- Prior art keywords
- aryl
- heteroaryl
- alkyl
- aryloxy
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/20—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
- C07D211/66—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having a hetero atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Abstract
具式(I)的化合物(其中R1,R2和Q的定义同上)对于下列疾病状态的治疗是有用的,其包括关节炎,癌症,组织溃疡形成,斑退化,(心瓣膜)再狭窄,牙周疾病,表皮松懈bullosa,巩膜炎,以及其他以基质金属蛋白酶活性为特征的疾病,AIDS,脓毒病,脓毒性休克以及其它涉及TNF生成的疾病。另外本发明化合物可与其它标准的非甾体抗炎药物(NSAID’S)以及止痛药合用进行治疗,在癌症的治疗中,其可与细胞毒药物(例如阿霉素,柔红霉素,顺铂,鬼臼乙叉甙,紫杉酚,紫杉烷衍生物以及生物碱,长春新碱)合用。
Description
本发明涉及芳基磺酰氨基异羟肟酸衍生物,其为基质金属蛋白酶或肿瘤坏死因子(TNF)产生的抑制剂,可以用来治疗下列疾病:关节炎,癌症,组织溃疡,斑退化,(心瓣膜)再狭窄,牙周疾病,大疱性表皮松懈,巩膜炎,以及其他以基质金属蛋白酶活性为特征的疾病,AIDS,脓毒症,脓毒性休克以及其它涉及TNF生成的疾病。另外本发明化合物可与其它标准的非甾体抗炎药物(NSAID’S)以及止痛药合用进行关节炎的治疗,还可与细胞毒药物(例如阿霉素,柔红霉素,顺铂,鬼臼乙叉甙,紫杉酚,紫杉烷衍生物(taxotere)以及生物碱,长春新碱)合用进行癌症的治疗。
本发明还涉及使用这类化合物来治疗哺乳动物(尤其是人类)体内的上述疾病的方法,本发明还涉及可用于上述方法中的药物组合物。
有许多酶可以破坏蛋白质的结构,它们在结构上与金属蛋白酶有关。基质降解金属蛋白酶(例如明胶酶,溶基质素和胶原酶)与组织基质降解有关(例如胶原萎陷),并且与许多涉及异常连接组织和底膜基质代谢的病原状况有关,例如关节炎(如骨关节炎和风湿性关节炎),组织溃疡形成,(如角膜、表皮和胃溃疡形成),异常创伤愈合,牙周疾病,骨病(如Paget’s疾病和骨质疏松),肿瘤转移或侵入,以及HIV-感染(
J.Leuk.Biol.,
52(2):244-248,1992)。
人们已认识到,肿瘤坏死因子(TNF)与许多感染和自身免疫疾病有关(W.Fiers,
FEBS Letters,1991,
285,199)。进一步地,已有显示,在脓毒病和脓毒性休克的炎症反应中,TNF是主要的递质(C.E.Spooner et al.,
Clinical Immunology and Immunopathology,1992,
62 S11)。
本发明涉及下式化合物或其药用盐,其中R1和R2各自独立为(C1-C6)烷基,三氟甲基,三氟甲基(C1-C6)烷基,(C1-C6)烷基(二氟亚甲基),(C1-C3)烷基(二氟亚甲基(C1-C3)烷基,(C6-C10)芳基,(C2-C9)杂芳基,(C6-C10)芳基(C1-C6)烷基,(C2-C9)杂芳基(C1-C6)烷基,或R1和R2一起构成(C3-C6)环烷基或苯并稠合(C3-C6)环烷基环或下式基团其中的n和m各自独立为1或2且X为CF2,S,O或NR3,其中R3为氢,(C1-C6)烷基,(C6-C10)芳基,(C2-C9)杂芳基,(C6-C10)芳基(C1-C6)烷基,(C2-C9)杂芳基(C1-C6)烷基,(C1-C6)烷基磺酰基,(C6-C10)芳基磺酰基或酰基;并且
Q为(C1-C6)烷基,(C6-C10)芳基,(C6-C10)芳氧基(C6-C10)芳基,(C6-C10)芳基(C6-C10)芳基,(C6-C10)芳基(C6-C10)芳基(C1-C6)烷基,(C6-C10)芳基(C2-C9)杂芳基,(C6-C10)芳氧基(C2-C9)杂芳基,(C2-C9)杂芳基,(C2-C9)杂芳基(C2-C9)杂芳基,(C2-C9)杂芳基(C6-C10)芳基,(C1-C6)烷基(C6-C10)芳基,(C1-C6)烷氧基(C6-C10)芳基,(C6-C10)芳基(C1-C6)烷氧基(C6-C10)芳基,(C6-C10)芳基(C1-C6)烷氧基(C1-C6)烷基,(C2-C9)杂芳氧基(C6-C10)芳基,(C1-C6)烷基(C2-C9)杂芳基,(C1-C6)烷氧基(C2-C9)杂芳基,(C6-C10)芳基(C1-C6)烷氧基(C2-C9)杂芳基,(C2-C9)杂芳氧基(C2-C9)杂芳基,(C6-C10)芳氧基(C1-C6)烷基,(C2-C9)杂芳氧基(C1-C6)烷基,(C1-C6)烷基(C6-C10)芳氧基(C6-C10)芳基,(C1-C6)烷基(C2-C9)杂芳氧基(C6-C10)芳基,(C1-C6)烷基(C6-C10)芳氧基(C2-C9)杂芳基,(C1-C6)烷氧基(C6-C10)芳氧基(C6-C10)芳基,(C1-C6)烷氧基(C2-C9)杂芳氧基(C6-C10)芳基或(C1-C6)烷氧基(C6-C10)芳氧基(C2-C9)杂芳基,其中的每一个芳基基团可以任意地被1-3个下面基团取代,氟,氯,溴,(C1-C6)烷基,(C1-C6)烷氧基或全氟(C1-C3)烷基(C6-C10)芳氧基,三氟甲氧基或二氟甲氧基取代。
除非另有说明,这里的术语“烷基”是指具有直链、支链或环状基团或其混合物的饱和单键烃类基团。
这里的术语“烷氧基”包括O-烷基基团,其中“烷基”的定义同上。
除非另有说明,这里的术语“芳基”包括衍生自移去一个氢原子后的芳烃有机基团,例如苯基或萘基,它们可以任意地被1-3个下列基团取代:氟,氯,溴,全氟(C1-C3)烷基,三氟甲基,(C1-C6)烷氧基,(C6-C10)芳氧基,三氟甲氧基,二氟甲氧基以及(C1-C6)烷基。
除非另有说明,这里的术语“杂环芳基”包括衍生自移去一个氢原子后的芳烃杂环化合物的有机基团,例如吡啶基,呋喃基,吡咯基,噻吩基,异噻唑基,咪唑基,苯并咪唑基,四唑基,吡嗪基,嘧啶基,喹啉基,异喹啉基,苯并呋喃基,异苯并呋喃基,苯并噻吩基,吡唑基,吲哚基,异吲哚基,嘌呤基,咔唑基,异噁唑基,噻唑基,噁唑基,苯并噻唑基或苯并噁唑基,它们可以任意地被1-2个下列基团取代:氟,氯,三氟甲基,(C1-C6)烷氧基,(C6-C10)芳氧基,三氟甲氧基,二氟甲氧基以及(C1-C6)烷基。
除非另有说明,这里的术语“酰基”包括具有通式RCO的基团,其中的R为烷基,烷氧基,芳基,芳烷基或芳烷氧基,并且术语“烷基”和“芳基”的定义同上。
这里的术语“酰氧基”包括O-酰基基团,其中“酰基”的定义同上。
式I的化合物可以具有手性中心,因此可以不同的的对映体形式存在。本发明涉及式I化合物所有的光学异构体和立体异构体以及它们的混合物。
优选的式I的化合物包括这些化合物,其中R1和R2一起构成(C3-C6)环烷基或苯并稠合(C3-C6)环烷基环或下式基团其中的n和m各自独立为1或2且X为CF2,S,O或NR3,其中R3为氢,(C1-C6)烷基,(C6-C10)芳基,(C2-C9)杂芳基,(C6-C10)芳基(C1-C6)烷基,(C2-C9)杂芳基(C1-C6)烷基,(C1-C6)烷基磺酰基,(C6-C10)芳基磺酰基或酰基。
其它优选的式I化合物包括那些化合物,其中的R1和R2一起构成(C3-C6)环烷基或苯并稠合(C3-C6)环烷基环。
其它优选的式I化合物包括那些化合物,其中Q为(C6-C10)芳基,(C6-C10)芳基(C6-C10)芳基,(C6-C10)芳氧基(C6-C10)芳基,(C6-C10)芳氧基(C2-C9)杂芳基,(C2-C9)杂芳基,(C2-C9)杂芳基(C2-C9)杂芳基,(C6-C10)芳基(C2-C9)杂芳基,(C2-C9)杂芳基(C6-C10)芳基或(C2-C9)杂芳氧基(C6-C10)芳基。
其它优选的式I的化合物包括那些化合物,其中Q为(C6-C10)芳氧基(C6-C10)芳基。
其它优选的式I化合物包括那些化合物,其中的R1和R2各自独立为(C1-C6)烷基。
更优选的式I的化合物包括那些化合物,其中的R1和R2一起构成(C3-C6)环烷基或苯并稠合(C3-C6)环烷基环或下式基团其中的n和m各自独立为1或2且X为CF2,S,O或NR3,其中R3为氢,(C1-C6)烷基,(C6-C10)芳基,(C2-C9)杂芳基,(C6-C10)芳基(C1-C6)烷基,(C2-C9)杂芳基(C1-C6)烷基,(C1-C6)烷基磺酰基,(C6-C10)芳基磺酰基或酰基;且Q为(C6-C10)芳基,(C6-C10)芳基(C6-C10)芳基,(C6-C10)芳氧基(C6-C10)芳基,(C6-C10)芳氧基(C2-C9)杂芳基,(C2-C9)杂芳基,(C2-C9)杂芳基(C2-C9)杂芳基,(C6-C10)芳基(C2-C9)杂芳基,(C2-C9)杂芳基(C6-C10)芳基或(C2-C9)杂芳氧基(C6-C10)芳基。
更优选的式I的化合物包括那些化合物,其中的R1和R2一起构成(C3-C6)环烷基或苯并稠合(C3-C6)环烷基环;并且Q为(C6-C10)芳基,(C6-C10)芳基(C6-C10)芳基,(C6-C10)芳氧基(C6-C10)芳基,(C6-C10)芳氧基(C2-C9)杂芳基,(C2-C9)杂芳基,(C2-C9)杂芳基(C2-C9)杂芳基,(C6-C10)芳基(C2-C9)杂芳基,(C2-C9)杂芳基(C6-C10)芳基或(C2-C9)杂芳氧基(C6-C10)芳基。
更优选的式I的化合物包括那些化合物,其中的R1和R2各自独立为(C1-C6)烷基,且Q为(C6-C10)芳基,(C6-C10)芳基(C6-C10)芳基,(C6-C10)芳氧基(C6-C10)芳基,(C6-C10)芳氧基(C2-C9)杂芳基,(C2-C9)杂芳基,(C2-C9)杂芳基(C2-C9)杂芳基,(C6-C10)芳基(C2-C9)杂芳基,(C2-C9)杂芳基(C6-C10)芳基或(C2-C9)杂芳氧基(C6-C10)芳基。
更优选的式I的化合物包括那些化合物,其中的R1和R2各自独立为(C1-C6)烷基;并且Q为(C6-C10)芳氧基(C6-C10)芳基。
具体的优选化合物包括下列化合物:
3-[4-(4-氟苯氧基)苯磺酰氨基]氮杂环丁烷-3-甲酸羟基酰胺;
4-[4-(4-氟苯氧基)苯磺酰氨基]哌啶-4-甲酸羟基酰胺;
1-[4-(4-氟苯氧基)苯磺酰氨基]环丙烷-1-甲酸羟基酰胺;
1-[4-(4-氯苯氧基)苯磺酰氨基]环丙烷-1-甲酸羟基酰胺;
1-[4-(4-氟苯氧基)苯磺酰氨基]环丁烷-1-甲酸羟基酰胺;
1-[4-(4-氯苯氧基)苯磺酰氨基]环丁烷-1-甲酸羟基酰胺;
1-[4-(4-氟苯氧基)苯磺酰氨基]环戊烷-1-甲酸羟基酰胺;
1-[4-(4-氟苯氧基)苯磺酰氨基]环己烷-1-甲酸羟基酰胺;
2-[4-(4-氟苯氧基)苯磺酰氨基]-N-羟基-2-甲基丙酰胺;
2-[4-(4-氯苯氧基)苯磺酰氨基]-N-羟基-2-甲基丙酰胺;
N-羟基-2-甲基-2-(5-吡啶-2-基噻吩-2-磺酰氨基)丙酰胺;
1-(5-吡啶-2-基-噻吩-2-磺酰氨基)环戊烷-1-甲酸羟基酰胺;
1-(4’-氟代联苯基-4-磺酰氨基)环丙烷-1-甲酸羟基酰胺;
1-(4’-氟代联苯基-4-磺酰氨基)环丁烷-1-甲酸羟基酰胺;
1-(4’-氟代联苯基-4-磺酰氨基)环戊烷-1-甲酸羟基酰胺;
2-(4-甲氧基苯磺酰氨基)1,2-二氢化茚-2-羧酸羟基酰胺;以及
2-[4-(4-氟苯氧基)苯磺酰氨基]1,2-二氢化茚-2-甲酸羟基酰胺。
本发明还涉及用于下列目的的药物组合物(a)与细胞毒抗肿瘤剂协同作用治疗下列疾病:关节炎,癌症,组织溃疡形成,斑退化,(心瓣膜)再狭窄,牙周疾病,大疱性表皮松懈,巩膜炎,与其它标准的NSAID’S和止痛药合用以及其它以基质金属蛋白酶活性为特征的疾病,AIDS,脓毒病,脓毒性休克以及其它涉及肿瘤坏死因子(TNF)生成的疾病,或(b)抑制哺乳动物(包括人类)体内基质金属蛋白酶或肿瘤坏死因子(TNF)的生成,其包括在这类治疗中,给予有效剂量的式I的化合物或其药用盐以及药用载体。
本发明涉及下述抑制方法抑制哺乳动物(包括人类)体内(a)基质金属蛋白酶或(b)肿瘤坏死因子(TNF)的生成,其包括给予所述哺乳动物有效剂量的式I化合物或其药用盐。
本发明还涉及治疗下列疾病的方法:关节炎,癌症,组织溃疡形成,斑退化,(心瓣膜)再狭窄,牙周疾病,大疱性表皮松懈,巩膜炎,与NSAID’S和止痛药合用,并且可与细胞毒抗肿瘤剂合用以及其它以基质金属蛋白酶活性为特征的疾病,AIDS,脓毒病,脓毒性休克以及其它涉及哺乳动物(包括人类)体内肿瘤坏死因子(TNF)生成的疾病,该方法包括,在这类治疗中给予所述哺乳动物有效剂量的式I的化合物或其药用盐。
下列路线将说明本发明化合物的制备。除非另有说明,反应路线和随后讨论中的R1,R2和Q的定义同上。
路线1
在制备A反应1中,于惰性溶剂中(例如苯或甲苯,甲苯为优选),用苄醇和具式HX的酸(其中X优选为4-甲苯磺酸盐)处理式III氨基酸,得到相应的式V苄酯酸盐。正常情况下,反应在所用溶剂的回流温度下进行1-24小时。此反应过程中形成的水用Dean-Strar捕获器进行收集。
在制备A反应2中,使V与磺酸(QSO2OH)的反应活性功能衍生物(如磺酰氯(QSO2Cl))在碱(如氢氧化钠或三乙胺)和溶剂(如二氯甲烷,四氢呋喃,二噁烷,水或乙腈,优选的是二噁烷和水的混合物)的存在下进行反应,使式V化合物转化为相应的式VI化合物。反应混合物在约0-50℃(最好是室温下)下搅拌10分钟-2天,优选的是约60分钟。
在制备A反应3中,将式VI中间体化合物氢解,得到中间体式II。反应于氢气下(优选的是3个大气压),在溶剂中(例如乙醇)使用10%Pd/C催化剂进行。室温下搅拌反应混合物约30分钟-24小时,优选的是1.5小时。
在路线1反应1中,使III与具式QSO2OH的磺酸的反应活性功能衍生物(其中Q的定义同上)(如磺酰氯(QSO2Cl))在碱(如氢氧化钠或三乙胺)和极性溶剂(如四氢呋喃,二噁烷,水或乙腈,优选的是二噁烷和水的混合物)的存在下进行反应,将式III化合物转化为相应的式II化合物。反应混合物在约0-50℃(最好是室温下)下搅拌10分钟-2天,优选的是约60分钟。
在路线1反应2中,使II与1-(3-二甲基氨基丙基)-3-乙基碳化二亚胺和1-羟基苯并***在极性溶剂(如N,N-二甲基甲酰胺)进行反应,约15分钟-1小时后(优选的是约30分钟),向反应混合物中加入羟胺,使式II化合物转化为式I异羟肟酸化合物。优选地,在碱存在下(如三乙胺),羟胺从其盐的形式就地生成,例如从羟胺盐酸盐。另外,也可以用羟胺的保护衍生物或其盐的形式(其中的羟基被叔丁基、苄基,烯丙基或2-三乙基甲硅烷基乙基醚保护)代替羟胺或羟胺盐酸盐。羟基保护基团的去除采用与苄基保护基团氢解一样的条件进行(优选的是以5%Pd/硫酸钡作催化剂),或采用叔丁基保护基去除的方法,即用强酸(如三氟乙酸)进行处理。在催化的双(三苯基膦)氯化钯(II)的存在下,用三丁基锡氢化物和乙酸进行处理,可以去除烯丙基保护基。使2-三甲基甲硅烷基乙基醚与强酸(如三氟乙酸)或与氟供给体(如三氟化硼醚化物)进行反应,可以去除2-三甲基甲硅烷基乙基醚。式II与羟胺,羟胺盐,羟胺保护衍生物或羟胺保护衍生物盐的反应可在(苯并***-1-基氧)三(二甲基氨基)-磷鎓六氟化磷酸盐(酯)和碱(如三乙胺)的存在下,于惰性溶剂(如二氯甲烷)中进行。反应混合物在0-50℃下(优选的是室温下)搅拌1小时-3天,优选的是1天。优选地,转化化合物II至化合物I的过程是使II与O-苄基羟胺盐酸盐在(苯并***-1-基氧)三(二甲基氨基)-磷鎓六氟磷酸盐(酯)和三乙胺存在下,于二氯甲烷中进行反应。室温3大气压氢气下,用5%Pd/硫酸钡作催化剂,进行氢解,去除O-苄基保护基团,得到式I化合物。优选的溶剂是甲醇。反应时间约为1-5小时(优选的是3.5小时)。
在某些情况下,优选的是使羟胺,羟胺盐,羟胺保护衍生物或羟胺保护衍生物盐与式IV活性酯进行反应,得到式I化合物,如路线1反应3所示。反应在惰性溶剂(如N,N-二甲基甲酰胺)中进行,反应温度约为室温至80℃,优选的是约50℃,反应时间约为1小时-2天。如果采用羟胺保护衍生物或羟胺保护衍生物的盐,则按上述方法去除保护基团。在惰性溶剂(例如二氯甲烷)中,用(苯并***-1-基氧)三(二甲基氨基)-磷鎓六氟磷酸(酯)和碱(如三乙胺)处理式II化合物可以得到式IV活性酯衍生物(见路线1反应4)。反应混合物在约0-50℃(优选的是室温)下搅拌约1小时-3天,优选的是1天。
本发明酸性化合物的药用盐是与碱形成的盐类,称为阳离子盐类,如碱和碱土金属盐,比如钠,锂,钾,钙,镁以及铵盐,如铵,三甲基铵,二乙基铵以及三(羟基甲基)-甲基铵盐。
相似地,酸加成盐(例如无机酸,有机羧酸和有机磺酸,如盐酸,甲磺酸,马来酸)也可以与碱性基团(如吡啶基)构成结构的一部分。
式I化合物或它们药用盐(下文中也称为本发明化合物)抑制基质金属蛋白酶或肿瘤坏死因子(TNF)生成的能力,以及它们治疗以基质金属蛋白酶或肿瘤坏死因子生成为特征的疾病的有效性的证明,可以参见下面的体外分析结果。
生物试验
人类胶原酶的抑制(MMP-1)
采用下列比例,使用胰蛋白酶可以活化人类重组胶原酶:每100μg胶原酶10μg胰蛋白酶。将胰蛋白酶和胶原蛋白在室温下培养10分钟。然后加入5倍过量的(50μg/10μg胰蛋白酶)大豆胰蛋白酶抑制剂。
在二甲亚砜中制备10mM的抑制剂贮备液,然后按下面稀释。
10mM→120μM→12μM→1.2μM→0.12μM
取每个浓度25mL溶液加到96孔显微平皿的合适孔内,每个样品制备三份。加入酶和底物后抑制剂的最终浓度按1∶4稀释。在D1-D6孔中建立阳性对照(有酶,无抑制剂),在D7-D12孔中建立空白对照(无酶,无抑制剂)。
将胶原酶稀释至400ng/mL,向上述显微平皿的合适孔内加入25μL该溶液。试验中胶原酶的最终浓度为100ng/mL。
制备5mM底物(DNP-Pro-Cha-Gly-Cys(Me)-His-Ala-Lys(NMA)-NH2)的二甲亚砜贮备溶液,然后用分析缓冲液稀释至20μM。在显微平皿的每个孔中加入50μL底物,得到的最终浓度为10μM,开始进行分析。
在0分钟以及每20分钟为一间隔时进行荧光读数(360nM激发,460nM发射)。分析在室温下进行,典型的分析时间为3小时。
然后就空白及含有样品的胶原酶的荧光相对于时间的结果绘图(取三个样品的平均数)。选择提供较好信号的时间点(空白)以及曲线上的直线部分时间点(通常在120分钟左右)来确定IC50值。零时刻被作为每个化合物在每个浓度下的空白,并且,这些值须从120分钟得到的数据中扣除。就抑制浓度相对于%对照样品的数据进行绘图(抑制剂荧光值除去单独胶源酶的荧光值×100)。给出相当于对照样品50%信号值时对应的抑制剂浓度被确定为IC50值。
如果报告的IC50值<0.03μM,则在0.3μM,0.03μM,0.03μM以及0.003μM浓度下分析抑制剂。
明胶酶抑制(MMP-2)
在与人类胶原酶抑制(MMP-1)相同的条件下,采用DNP-Pro-Cha-Gly-Cys(Me)-His-Ala-Lys(NMA)-NH2底物(10μM)分析明胶酶的活性。
在4℃下,用1mMAPMA(对氨基苯基乙酸汞)使72KD的明胶酶活化,并将其稀释至最终浓度为100mg/mL。将用于抑制人类胶原酶(MMP-1)的抑制剂进行稀释,得到最终浓度为30μM,3μM,0.3μM和0.03μM,每个浓度制备3份。
在0分钟以及每20分钟为一间隔时进行荧光读数(360nM激发,460nM发射),共持续4小时。
测定每一个人类胶原酶(MMP-1)的抑制。如果报告的IC50值<0.03μM,则在0.3μM,0.03μM,0.003μM以及0.003μM的最终浓度下检测抑制剂。
溶基质素活性的抑制(MMP-3)
溶基质素活性抑制是基于Weingarten和Feder(Weingarten,H.和Feder,J.,Spectrophotometric Assay for VertebrateCollagenase,Anal.Biochem.
147,437-440(1985))所描述的改进的分光光度分析法进行的。硫代肽酯(peptolide)底物[Ac-Pro-Leu-Gly-SCH[CH2CH(CH3)2]CO-Leu-Gly-OC2H5]的水解产生了硫醇片断,在Ellman’s试剂的存在下,可对其进行监测。
用胰蛋白酶活化人类重组前溶基质素,使用比例为每26μg溶基质素1μL的10mg/mL胰蛋白酶贮备液。胰蛋白酶和溶基质素在37℃下培养15分钟,接着与10μL 10mg/mL大豆胰蛋白酶抑制剂于37℃下培养10分钟以终止胰蛋白酶活性。
用96孔显微平皿并在总体积为250μL的分析缓冲液(200mM氯化钠,50mM MES以及10mM氯化钙,pH6.0)中进行分析。用分析缓冲液将活化的溶基质素稀释至25μg/mL。在二甲基甲酰胺中制备1M的Ellman’s试剂(3-羧基-4-硝基苯基二硫化物)储备溶液,并用缓冲液稀释至浓度为5mM,以使在每孔50μL加量下可以产生1mM的最终浓度。
在二甲基亚砜中制备10mM抑制剂贮备溶液,并用缓冲液进行系列稀释,以便将50μL该溶液加到合适的孔中时,可以产生的最终浓度为3μM,0.3μM,0.003μM以及0.0003μM。所有的条件制备3份样品。
用分析缓冲液将300mM肽底物的二甲基亚砜贮备溶液稀释到15mM,向每孔中加入50μL该溶液后得到最终浓度为3mM的底物,开始进行分析。背景含有肽底物和Ellman’s试剂,但没有酶。用Molecular Devices Uvmax平皿读数器在405nm处监测产品的形成。
用与同胶原酶相同的方法测定IC50值。
MMP-13的抑制
37℃下,用2mM APMA(对氨基苯基乙酸汞)使人类重组MMP-13活化1.5小时,并用分析缓冲液(50mM Tris,pH7.5,200mM氯化钠,50mM氯化钙,20μM氯化锌以及0.02% brij)将其稀释至400mg/ml。96孔显微平皿的每一个孔中加25μl稀释液。在分析缓冲液中以1∶4的比例加入抑制剂和底物对酶进行稀释,使其在分析缓冲液中的最终浓度为100mg/ml。
在二甲基亚砜中制备10mM抑制剂贮备溶液,并按照用于抑制人类胶原酶(MMP-1)的抑制剂稀释路线用缓冲液对其进行稀释,向显微平皿中加入25μl各个浓度的溶液,每个样品制备3份。分析缓冲液中的最终浓度为30μM,3μM,0.3μM和0.03μM。
制备用于抑制人类胶原酶(MMP-1)的底物(Dnp-Pro-Cha-Gly-Cys(Me)-His-Ala-Lys(NNA)-NH2],并向每孔中加入50μL该溶液,使最终的分析浓度为10μM。在0时刻以及每5分钟时进行荧光读数(360nM激发,450nM发射),持续1小时。
阳性对照含有酶和底物,但不含抑制剂,空白仅含有底物。
用与同人类胶原酶(MMP-1)相同的方法测定IC50值。如果报告的IC50值<0.03μM,则在0.3μM,0.03μM,0.003μM以及0.0003μM的最终浓度下进-步分析抑制剂。
TNF生成的抑制
下列体外分析显示了化合物或其药用盐抑制TNF生成的能力并随之证明了它们在治疗与TNF生成有关疾病方面的效力:
采用一步Ficoll-hypaque(3,5-二乙酰胺基-2,4,6-三碘苯甲酸钠)分离技术,从人抗凝血中将人类单核细胞分离出来。(2)在Hanks平衡盐溶液(HBSS)中,用二价阳离子溶液将单核细胞洗涤三次,并将其再悬浮于含有1%BSA、密度为2×106/ml的HBSS中。用Abbott Cell Dyn 3500分析仪测定得到的分化计数表明:在这些制备物中,单细胞占细胞总数的17-24%。
将180μL细胞悬浮物等分到96孔平皿的平整底部(Costar)。加入化合物和LPS(最终浓度为100ng/ml),最终体积达到200μL。所有条件制备3份。在一个加湿二氧化碳培养器中培养4小时后,移去平皿,离心(大约250×g,10分钟),除去上清液,用R&D ELISAKit分析TNFa。
就哺乳动物(包括人类)的给药来说,为了抑制基质金属蛋白酶或肿瘤坏死因子(TNF)的生成,可以采用各种常规的给药途径,包括口服、非肠道以及局部给药。通常活性成分以口服或非肠道途径给药,剂量在约0.1至25mg/Kg接受者体重/每天,优选的是0.3至5mg/Kg。然而,根据接受治疗对象的情况,剂量可进行必要的变化。在任何情况下,负责给药的人将根据给药对象的情况来决定合适的给药剂量。
本发明化合物可以很多不同的剂型给药,一般来说,上述剂型的治疗有效剂量的本发明化合物的浓度水平在约5.0%至70%(重量比)。
对于口服给药而言,可以采用含有各种赋形剂(例如微晶纤维素,柠檬酸钠,碳酸钙,磷酸二钙以及甘油)的片剂,其可带有各种崩解剂,例如淀粉(优选的是玉米、土豆或木著淀粉),藻酸以及某些复合硅酸盐,还可以含有粒化粘合剂,如聚乙烯吡咯烷酮,蔗糖,明胶以及金合欢素。另外,片剂中还常使用润滑剂,例如硬脂酸镁,月桂基硫酸钠以及滑石。相似类型的固体组合物也被用作明胶胶囊中的填充剂;在这种情况中,优选的材料包括乳糖或牛奶糖以及高分子量的聚乙二醇。当需要水合悬浮液和/或酏剂进行口服给药时,可将活性成分与各种增甜剂或增味剂,增色物质以及染料合用,并且如有所需,还可与乳化剂及悬浮剂合用,同时其还可以含有稀释剂,如水,乙醇,丙二醇,甘油以及各种它们的组合物质。在进行动物给药时,较好的是将这些物质含于动物饲料或饮用水中,浓度为5-5000ppm,优选的是25-500ppm。
对于非肠道给药(肌内,腹膜内,皮下以及静脉内)来说,通常是制备活性成分的无菌注射溶液。可以应用本发明治疗化合物的芝麻油或花生油溶液,或者是丙二醇的水溶液。水溶液应适当调节和缓冲,优选的是pH大于8,如有所需,须首先使液体稀释剂等渗。这些水溶液适合于静脉给药。油性溶液适合于关节内,肌内和皮下注射给药。采用本领域内专家们熟知的方法,可以方便地在无菌条件下完成所有这些溶液的制备。在进行动物给药时,可以采用肌内和皮下注射给药,剂量水平在约0.1-50mg/Kg/天,优选的是0.2-10mg/Kg/天,可以采取单一剂量或多至3个分开剂量进行给药。
下列实施例将说明本发明,但并不限制本发明的详细内容。
制备A
4-(4-氟苯氧基)苯磺酰基氯化物
在机械搅拌下,将氯代磺酸(26ml,0.392mole)滴加到冰冷的4-氟代苯氧基苯(36.9g,0.196mole)。加入完毕,混合物于室温下搅拌4小时。将其倾入冰水中。滤集产品4-(4-氟苯氧基)苯磺酰基氯化物(18.6g,33%),并在空气中干燥。
制备B
4-(3-甲基丁氧基)苯磺酸钠
使4-羟基苯磺酸(10.0g,43.1mmole)以及氢氧化钠(3.3g,83mole)的水溶液(40mL)与1-碘-3-甲基丁烷(11.3mL,86.4mmole)的异丙醇溶液(60mL)进行混合,生成的混合物加热回流2天。减压蒸除异丙醇。过滤并用异丙醇洗涤,得到10.0g(87%)标题化合物。
制备C
4-(3-甲基丁氧基)苯磺酰氯
使4-(3-甲基丁氧基)苯磺酸钠(2.5g,9.4mmole),亚硫酰氯(10mL)以及5滴N,N-二甲基甲酰胺的混合物一起回流5小时。冷却后,蒸除多余的亚硫酰氯,残渣溶于乙酸乙酯中。溶液在冰浴上冷却,加水。分出有机相,用水和盐水洗涤。硫酸钠干燥后,蒸除溶剂,得到2.4g(95%)标题化合物,其为油状物。
制备D
4-(2-环戊基乙氧基)苯磺酸钠
将4-羟基苯磺酸(65g,282mmole)以及氢氧化钠(2.2g,55mole)的水溶液(15mL)与2-(溴乙基)环戊烷(15.0g,84.7mmole)的异丙醇溶液(40mL)进行混合,生成的混合物加热回流2天。减压蒸除异丙醇。过滤并用异丙醇洗涤,得到4.7g(57%)标题化合物。
制备E
4-(3-甲基丁氧基)苯磺酰氯
使4-(2-环戊基乙氧基)苯磺酸钠(2.5g,8.6mmole),亚硫酰氯(15mL)以及几滴N,N-二甲基甲酰胺的混合物一起回流5小时。冷却后,蒸除多余的亚硫酰氯,残渣溶于乙酸乙酯中。溶液在冰浴上冷却,加水。分出有机相,用水和盐水洗涤。硫酸钠干燥后,蒸除溶剂,得到2.24g(90%)标题化合物,其为油状物。
制备F
4’-氟代联苯基磺酰基氯化物
在冰浴搅拌下,将氯代磺酸(8.7mL,0.13mole)滴加到4-氟代联苯(10.2g,59mole)中。冰浴下继续搅拌0.5小时,然后将混合物倾入冰中。滤集生成的白色沉淀并将其溶于氯仿中。用水和盐水洗涤氯仿溶液,硫酸镁干燥,浓缩,得到一白色固体。通过用乙酸乙酯对其进行重结晶,将所需产品4’-氟代联苯基磺酰基氯化物(4.3g,27%)从4’-氟代联苯基磺酸(不想要的副产物)中分离出来,剩余的物质用己烷进行重结晶。
制备G
4-(4-氟代苄氧基)苯磺酸钠
向4-羟基苯磺酸(513g,221mmole)的1N氢氧化钠水溶液(23mL)中加入4-氟代溴苄(33mL,265mmole)的乙醇溶液(20mL)。生成的混合物加热回流2天。冷却并放置后,出现白色沉淀。滤集沉淀,并用乙酸乙酯和***进行洗涤,得到4.95g(74%)4-(4-氟代苄氧基)苯磺酸钠。
制备H
4-(4-氟代苄氧基)苯磺酰氯
向4-(4-氟代苄氧基)苯磺酸钠(0.5g,1.64mmole)的二氯甲烷(5mL)浆状物中加入五氯化磷(275mg,1.31mmole)。生成的混合物一起回流7小时。冰浴冷却后用水(15mL)终止反应,用乙酸乙酯提取。有机相用盐水洗涤。硫酸钠干燥后,蒸除溶剂,得到4-(4-氟代苄氧基)苯磺酰氯(130mg,26%),其为白色固体。
制备I
4-(4-氯代苄氧基)苯磺酰氯
室温搅拌下,将氯代苯磺酸(9.7mL,0.147mole)滴加到4-氯代苯氧基苯(12.6mL,73.4mmole)中。加入完毕,生成的混合物于室温下搅拌1小时,然后将其倾入冰水中。滤集固体,空气中干燥,用石油迷和乙酸乙酯重结晶,得到4-(4-氯代苄氧基)苯磺酰氯(7.43g,33%)
实施例1 1-(4-甲氧基苯磺酰基氨基)环戊烷-1-甲酸羟基酰胺
(A)向1-氨基环戊烷-1-甲酸(6.0g,46.5mmole)和三乙胺(14mL,100mmole)的二噁烷(90mL)和水(90mL)溶液中加入4-甲氧基苯磺酰氯(10.6g,51.3mmole)。混合物于室温下搅拌4小时,用1N盐酸溶液酸化,乙酸乙酯提取两次。合并的乙酸乙酯提取液用盐水洗涤,硫酸镁干燥,浓缩,得到一个褐色固体,用氯仿研制,5.42g(39%)得到1-(4-甲氧基苯磺酰基氨基)环戊烷-1-甲酸,其为白色固体。
(B)向1-(4-甲氧基苯磺酰基氨基)环戊烷-1-甲酸(4.65g,15.2mmole)和三乙胺(2.5mL,17.9mmole)的二氯甲烷(120mL)溶液中加入(苯并***-1-基氧)三(二甲基氨基)-磷鎓六氟磷酸盐(酯)(7.4g,16.3mmole)。混合物于室温下搅拌2.5天。蒸除溶剂,残渣用乙酸乙酯提取。溶液依次用0.5N盐酸溶液,水和盐水洗涤。硫酸镁干燥后浓缩溶剂,得到1-(4-甲氧基苯磺酰基氨基)环戊烷-甲酸苯并***-1-基酯,其为黄色固体。将其溶于N,N-二甲基甲酰胺(120mL)中,向生成的溶液中加入二异丙基乙基胺(5.3mL,30mmole)和O-苄基羟胺盐酸盐(3.2g,20mmole)。混合物在50℃的油浴上加热20小时。蒸除溶剂,加入乙酸乙酯。过滤混合物,收集白色固体。滤液依次用0.5N盐酸溶液,饱和碳酸氢钠水溶液和盐水洗涤。蒸除溶剂,得到的固体与前述过滤得到的固体合并,用乙酸乙酯研制,得到2.92g(47%)1-(4-甲氧基苯磺酰基氨基)环戊烷-1-甲酸苄氧基酰胺,其为白色固体。
(C)用5%Pd/硫酸钡(0.75g)处理1-(4-甲氧基苯磺酰基氨基)环戊烷-1-甲酸苄氧基酰胺(1.50mL,3.71mmole)的甲醇溶液(200mL),并在3个大气压下,于Parr shaker中进行氢化3.5小时。使混合物通过0.45μm的尼龙过滤器,滤液浓缩,得到1.13g(97%)1-(4-甲氧基苯磺酰基氨基)环戊烷-1-甲酸羟基酰胺,其为白色固体。MS:313(M-1)。
采用与实施例1中相似的方法,使用下列试剂,可以制备实施例2-8中的标题化合物。
实施例2 1-(4-甲氧基苯磺酰基氨基)环己烷-1-甲酸羟基酰胺
1-氨基环己烷-1-甲酸;4-甲氧基苯磺酰氯。MS:327(M-1)。
实施例31-[4-(4-氟苯氧基)苯磺酰氨基]环戊烷-1-甲酸羟基酰胺
1-氨基环戊烷-1-甲酸;4-(4-氟苯氧基)苯磺酰氯。MS:393(M-1)。元素分析(C18H19FN2O5S.0.25H2O)理论值:C 54.19,H4.93,N 7.02。实测值:C 54.20,H 5.13,N 7.08
实施例4 1-[4-(4-氟苯氧基)苯磺酰氨基]环己烷-1-甲酸羟基酰胺
1-氨基环己烷-1-甲酸;4-(4-氟苯氧基)苯磺酰氯。氯仿重结晶。MP:174℃;MS:393(M-1)。
实施例5 1-[4-(4-氟苯氧基)苯磺酰氨基]环丙烷-1-甲酸羟基酰胺
1-氨基环丙烷-1-甲酸;4-(4-氟苯氧基)苯磺酰氯。MP:184℃;MS:365(M-1);元素分析(C16H15FN2O5S)理论值:C 52.45,H4.13,N 7.65。实测值:C 52.20,H 4.34,N 7.44。
实施例6 1-(4’-氟代联苯基-4-磺酰氨基)环戊烷-1-甲酸羟基酰胺
1-氨基环戊烷-1-甲酸;4’-氟代联苯基磺酰氯。氯仿重结晶。MP:159℃;MS:377(M-1)。
实施例7 1-[4-(4-氟苯氧基)苯磺酰氨基]环丁烷-1-甲酸羟基酰胺
1-氨基环丁烷-1-甲酸;4-(氟苯氧基)苯磺酰氯。MS:379(M-1)。
实施例8 1-[4-(4-氟苯氧基)苯磺酰氨基]环丙烷-1-甲酸羟基酰胺
1-氨基环丙烷-1-甲酸;4-(4-氟苯氧基)苯磺酰氯。MS:379(M-1)。
实施例9 N-羟基-2-(4-甲氧基苯磺酰氨基)-2-甲基丙酰胺
(A)在冰浴上,将2-氨基-2-甲基丙酸苄酯盐酸盐(12.0g,52.2mmole)和4-甲氧基苯磺酰(11.9g,57.6mmole)的二噁烷溶液(100mL)以及水(100mL)进行冷却。加入三乙胺(18.2mL,0.13mole)。移去冰浴,混合物于室温下搅拌2天。减压蒸除溶剂,残余物溶于乙酸乙酯和水,分出水层,用乙酸乙酯提取两次,合并的有机层依次用饱和碳酸氢钠水溶液、1N盐酸以及盐水洗涤。硫酸钠干燥后,蒸发溶剂,得到黄色油状物(19.3g),其中的一部分(10g)用硅胶层析纯化,以3∶7的乙酸乙酯/己烷进行洗脱,乙酸乙酯/己烷重结晶后,得到6.59g(67%)2-(4-甲氧基苯磺酰氨基)-2-甲基丙酸苄酯,其为白色固体。
(B)在Parr振荡器中,用10%Pd/C(0.17g)和3大气压的氢气对2-(4-甲氧基苯磺酰氨基)-2-甲基丙酸苄酯(1.5g,4.13mmole)的乙醇溶液(80mL)处理1.5小时。使混合物通过0.45μm的尼龙过滤器除去催化剂,浓缩滤液,得到1.09g(96%)2-(4-甲氧基苯磺酰氨基)-2-甲基丙酸,其为白色固体。
(C)将2-(4-甲氧基苯磺酰氨基)-2-甲基丙酸(1.08g,3.95mmole)的二氯甲烷(120mL)溶液在冰浴上进行冷却。依次加入三乙胺(2.2mL,15.8mmole),(苯并***-1-基氧)三(二甲基氨基)-磷鎓六氟磷酸(酯)盐(2.6g,5.88mmole)以及O-苄基羟胺盐酸盐(0.95g,5.95mmole)。生成的混合物于室温下搅拌16小时。蒸除溶剂,残余物溶于用乙酸乙酯和水,溶液依次用1N盐酸,饱和碳酸氢钠水溶液,水及盐水洗涤。硫酸钠干燥后,蒸发溶剂,得到油状物。对其进行硅胶层析纯化,以1∶2的乙酸乙酯/己烷进行洗脱,得到1.41g(95%)所需的N-苄氧基-2-(4-甲氧基苯磺酰氨基)-2-甲基丙酰胺,其为白色固体。
(D)在Parr振荡器中,用5%Pd/硫酸钡(0.75g)和3大气压的氢气对N-苄氧基-2-(4-甲氧基苯磺酰氨基)-2-甲基丙酰胺,(1.40g,3.70mmole)的甲醇溶液(80mL)处理1.5小时。使混合物通过0.45μm尼龙过滤器,除去催化剂,浓缩滤液,得到1.06g(100%)N-羟基-2-(4-甲氧基苯磺酰氨基)-2-甲基丙酰胺,其为白色固体。MP:122-125℃,MS:289(M+1):元素分析(C11H16N2O5S)理论值:C 45.82,H 5.59,N 9.72;实测值:C 45.88,H 5.60,N 9.69。
采用与实施例9中相似的方法,使用下列试剂,可以制备实施例10-12中的标题化合物。
实施例10 2-[4-(4-氟苯氧基)苯磺酰氨基]-N-羟基-2-甲基丙酰胺
2-氨基-2-甲基丙酸苄酯盐酸盐;4-(4-氟苯氧基)苯磺酰氯。MP:133-134℃,MS:369(M+1):元素分析(C16H17FN2O5S)理论值:C 52.17,H 4.65,N 7.60;实测值:C 52.21,H 4.83,N 7.80。
实施例11 N-羟基-2-甲基-2-[4-(3-甲基丁氧基)苯磺酰氨基]-丙酰胺
2-氨基-2-甲基丙酸苄酯盐酸盐;4-(3-甲基丁氧基)苯磺酰氯。乙酸乙酯/己烷重结晶。MP:126.5-128℃,MS:343(M-1):元素分析(C15H24N2O5S)理论值:C 52.31,H 7.02,N 8.13;实测值:C 52.30,H 7.07,N 8.16。
实施例12 2-[4-(2-环戊基乙氧基)苯磺酰氨基]-N-羟基-2-甲基-丙酰胺
2-氨基-2-甲基丙酸苄酯盐酸盐;4-(2-环戊基乙氧基)苯磺酰氯。乙酸乙酯/己烷重结晶。MP:126-127℃,MS:369(M-1):元素分析(C17H26N2O5S)理论值:C 55.12,H 7.07,N 7.56;实测值:C 55.46,H 7.09,N 7.38。
实施例13 N-羟基-2-甲基-2-(5-吡啶-2-基噻吩-2-磺酰氨基)-丙酰胺
(A)向2-氨基-2-甲基丙酸(2.0g,19.4mmole)的1N氢氧化钠溶液(45mL)中加入5-吡啶-2-基噻吩-2-磺酰氯(8.41g,32.4mmole)。生成的混合物于室温下搅拌16小时。再向其中加入1N氢氧化钠溶液(45mL),用***提取。弃去有机层,水层用1N盐酸溶液酸化,乙酸乙酯提取。乙酸乙酯部分用盐水洗涤。硫酸钠干燥后,浓缩,得到2.18g(34%)2-甲基-2-(5-吡啶-2-基噻吩-2-磺酰氨基)丙酸,其为白色固体。
(B)向2-甲基-2-(5-吡啶-2-基噻吩-2-磺酰氨基)丙酸(1.60g,4.91mmole)的二氯甲烷(160ml)溶液中加入三乙胺(2.3mL,16.5mmole),(苯并***-1-基氧)三(二甲基氨基)-磷鎓六氟磷酸盐(酯)(2.4g,5.41mmole)以及O-(2-三甲基甲硅烷基乙基)羟胺盐酸盐(0.92g,5.41mmole)。生成的混合物于室温下搅拌16小时。蒸除溶剂,残渣用乙酸乙酯和水提取。溶液依次用水,1N盐酸,饱和碳酸氢钠水溶液及盐水洗涤。硫酸钠干燥后,蒸发溶剂,得到白色泡沫状物。对其进行硅胶层析纯化,以3∶2的乙酸乙酯/己烷进行洗脱,得到220mg(10%)所需的2-甲基-2-(5-吡啶-2-基噻吩-2-磺酰氨基)-N-2-(三甲基硅烷基乙氧基)丙酰胺,其为白色固体。
(C)将2-甲基-2-(5-吡啶-2-基噻吩-2-磺酰氨基)-N-2-(三甲基硅烷基乙氧基)丙酰胺(80mg,0.18mmole)溶于三氟乙酸中,生成的混合物于室温下搅拌16小时。减压蒸除三氟乙酸,用甲醇使之溶解,得到N-羟基-2-甲基-2-(5-吡啶-2-基噻吩-2-磺酰氨基)-丙酰胺(60mg,97%),其为黄色油状物,再用乙醇重结晶。MP:165-166℃。MS:342(M+1)。
采用与实施例13中相似的方法,使用下列试剂,可以制备实施例14-15中的标题化合物。
实施例14 1-(5-吡啶-2-基-噻吩-2-磺酰氨基)环戊烷-1-甲酸羟基酰胺
1-氨基环戊烷-1-甲酸;5-吡啶-2-基噻吩-2-磺酰氯。MS:368(M+1)。
实施例15 1-[4-(4-氯苯氧基)苯磺酰氨基]环丙烷-1-甲酸羟基酰胺
1-氨基环丙烷-1-甲酸;4-(4-氯苯氧基)苯磺酰氯。MS:381(M-1)。
Claims (14)
1、具下式的化合物或其药用盐,
其中R1和R2各自独立为(C1-C6)烷基,三氟甲基,三氟甲基(C1-C6)烷基,(C1-C6)烷基(二氟亚甲基),(C1-C3)烷基(二氟亚甲基(C1-C3)烷基,(C6-C10)芳基,(C2-C9)杂芳基,(C6-C10)芳基(C1-C6)烷基,(C2-C9)杂芳基(C1-C6)烷基,或R1和R2一起构成(C3-C6)环烷基或苯并稠合(C3-C6)环烷基环或下式基团其中的n和m各自独立为1或2且X为CF2,S,O或NR3,其中R3为氢,(C1-C6)烷基,(C6-C10)芳基,(C2-C9)杂芳基,(C6-C10)芳基(C1-C6)烷基,(C2-C9)杂芳基(C1-C6)烷基,(C1-C6)烷基磺酰基,(C6-C10)芳基磺酰基或酰基;并且
Q为(C1-C6)烷基,(C6-C10)芳基,(C6-C10)芳氧基(C6-C10)芳基,(C6-C10)芳基(C6-C10)芳基,(C6-C10)芳基(C6-C10)芳基(C1-C6)烷基,(C6-C10)芳基(C2-C9)杂芳基,(C6-C10)芳氧基(C2-C9)杂芳基,(C2-C9)杂芳基,(C2-C9)杂芳基(C2-C9)杂芳基,(C2-C9)杂芳基(C6-C10)芳基,(C1-C6)烷基(C6-C10)芳基,(C1-C6)烷氧基(C6-C10)芳基,(C6-C10)芳基(C1-C6)烷氧基(C6-C10)芳基,(C6-C10)芳基(C1-C6)烷氧基(C1-C6)烷基,(C2-C9)杂芳氧基(C6-C10)芳基,(C1-C6)烷基(C2-C9)杂芳基,(C1-C6)烷氧基(C2-C9)杂芳基,(C6-C10)芳基(C1-C6)烷氧基(C2-C9)杂芳基,(C2-C9)杂芳氧基(C2-C9)杂芳基,(C6-C10)芳氧基(C1-C6)烷基,(C2-C9)杂芳氧基(C1-C6)烷基,(C1-C6)烷基(C6-C10)芳氧基(C6-C10)芳基,(C1-C6)烷基(C2-C9)杂芳氧基(C6-C10)芳基,(C1-C6)烷基(C6-C10)芳氧基(C2-C9)杂芳基,(C1-C6)烷氧基(C6-C10)芳氧基(C6-C10)芳基,(C1-C6)烷氧基(C2-C9)杂芳氧基(C6-C10)芳基或(C1-C6)烷氧基(C6-C10)芳氧基(C2-C9)杂芳基,其中的每一个芳基基团可以任意地被氟,氯,溴,(C1-C6)烷基,(C1-C6)烷氧基或全氟(C1-C3)烷基取代。
2、权利要求1中的化合物,其中的R1和R2一起构成(C3-C6)环烷基或苯并稠合(C3-C6)环烷基环或下式基团其中的n和m各自独立为1或2且X为CF2,S,O或NR3,其中R3为氢,(C1-C6)烷基,(C6-C10)芳基,(C2-C9)杂芳基,(C6-C10)芳基(C1-C6)烷基,(C2-C9)杂芳基(C1-C6)烷基,(C1-C6)烷基磺酰基,(C6-C10)芳基磺酰基或酰基。
3、权利要求2中的化合物,其中的R1和R2一起构成(C3-C6)环烷基或苯并稠合(C3-C6)环烷基环。
4、权利要求1中的化合物,其中的Q为(C1-C6)烷基,(C6-C10)芳基(C6-C10)芳基,(C6-C10)芳氧基(C6-C10)芳基,(C6-C10)芳氧基(C2-C9)杂芳基,(C2-C9)杂芳基,(C2-C9)杂芳基(C2-C9)杂芳基,(C6-C10)芳基(C2-C9)杂芳基,(C2-C9)杂芳基(C6-C10)芳基或(C2-C9)杂芳氧基(C6-C10)芳基。
5、权利要求4中的化合物,其中的Q为(C6-C10)芳氧基(C6-C10)芳基。
6、权利要求1中的化合物,其中的R1和R2各自独立地为(C1-C6)烷基。
7、权利要求1中的化合物,其中的R1和R2一起构成(C3-C6)环烷基或苯并稠合(C3-C6)环烷基环或下式基团其中的n和m各自独立为1或2且X为CF2,S,O或NR3,其中R3为氢,(C1-C6)烷基,(C6-C10)芳基,(C2-C9)杂芳基,(C6-C10)芳基(C1-C6)烷基,(C2-C9)杂芳基(C1-C6)烷基,(C1-C6)烷基磺酰基,(C6-C10)芳基磺酰基或酰基;且Q为(C6-C10)芳基,(C6-C10)芳基(C6-C10)芳基,(C6-C10)芳氧基(C6-C10)芳基,(C6-C10)芳氧基(C2-C9)杂芳基,(C2-C9)杂芳基,(C2-C9)杂芳基(C2-C9)杂芳基,(C6-C10)芳基(C2-C9)杂芳基,(C2-C9)杂芳基(C6-C10)芳基或(C2-C9)杂芳氧基(C6-C10)芳基。
8、权利要求1中的化合物,其中的R1和R2一起构成(C3-C6)环烷基或苯并稠合(C3-C6)环烷基环;并且Q为(C6-C10)芳基,(C6-C10)芳基(C6-C10)芳基,(C6-C10)芳氧基(C6-C10)芳基,(C6-C10)芳氧基(C2-C9)杂芳基,(C2-C9)杂芳基,(C2-C9)杂芳基(C2-C9)杂芳基,(C6-C10)芳基(C2-C9)杂芳基,(C2-C9)杂芳基(C6-C10)芳基或(C2-C9)杂芳氧基(C6-C10)芳基。
9、权利要求1中的化合物,其中的R1和R2各自独立为(C1-C6)烷基,且Q为(C6-C10)芳基,(C6-C10)芳基(C6-C10)芳基,(C6-C10)芳氧基(C6-C10)芳基,(C6-C10)芳氧基(C2-C9)杂芳基,(C2-C9)杂芳基,(C2-C9)杂芳基(C2-C9)杂芳基,(C6-C10)芳基(C2-C9)杂芳基,(C2-C9)杂芳基(C6-C10)芳基或(C2-C9)杂芳氧基(C6-C10)芳基。
10、权利要求1中的化合物,其中的R1和R2各自独立为(C1-C6)烷基;并且Q为(C6-C10)芳氧基(C6-C10)芳基。
11、权利要求1中的化合物,其中所述的化合物选自下列化合物:
1-[4-(4-氟苯氧基)苯磺酰氨基]环丙烷-1-甲酸羟基酰胺;
1-[4-(4-氯苯氧基)苯磺酰氨基]环丙烷-1-甲酸羟基酰胺;
1-[4-(4-氟苯氧基)苯磺酰氨基]环丁烷-1-甲酸羟基酰胺;
1-[4-(4-氟苯氧基)苯磺酰氨基]环戊烷-1-甲酸羟基酰胺;
1-[4-(4-氟苯氧基)苯磺酰氨基]环己烷-1-甲酸羟基酰胺;
2-[4-(4-苯氧基)苯磺酰氨基)-N-羟基-2-甲基丙酰胺;
2-[4-(4-氟苯氧基)苯磺酰氨基]-N-羟基-2-甲基丙酰胺;
N-羟基-2-甲基-2-(5-吡啶-2-基噻吩-2-磺酰氨基)丙酰胺;
1-(5-吡啶-2-基-噻吩-2-磺酰氨基)环戊烷-1-甲酸羟基酰胺;
N-羟基-2-甲基-2-[4-(3-甲基丁氧基)苯磺酰氨基]-丙酰胺;
1-(4’-氟代联苯基-4-磺酰氨基)环戊烷-1-甲酸羟基酰胺;
2-[4-(2-环戊基乙氧基)苯磺酰氨基]-N-羟基-2-甲基-丙酰胺。
12、用于(a)与NASID和止痛药联用或与细胞毒抗癌药联用治疗关节炎,癌症,组织溃疡形成,斑退化,心瓣膜再狭窄,牙周疾病,大疱性表皮松懈,巩膜炎,AIDS,脓毒病,脓毒性休克或(b)抑制包括人类哺乳动物体内基质金属蛋白酶或肿瘤坏死因子的生成的药物组合物,其包括治疗有效剂量的权利要求1化合物和药用载体。
13、式I化合物在制备用于抑制(a)包括人类哺乳动物体内基质金属蛋白酶或(b)肿瘤坏死因子生成的药物中用途。
14、权利要求1化合物与NSAID和止痛药联用及与细胞毒抗肿瘤剂联用在制备用于治疗下列疾病的药物中用途:关节炎,癌症,组织溃疡形成,斑退化,心瓣膜再狭窄,牙周疾病,大疱性表皮松懈,巩膜炎,AIDS,脓毒病,脓毒性休克。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3685797P | 1997-02-03 | 1997-02-03 | |
US60/036,857 | 1997-02-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1249743A CN1249743A (zh) | 2000-04-05 |
CN1113862C true CN1113862C (zh) | 2003-07-09 |
Family
ID=21891041
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN98802991A Expired - Fee Related CN1113862C (zh) | 1997-02-03 | 1998-01-12 | 芳基磺酰氨基异羟肟酸衍生物 |
Country Status (43)
Families Citing this family (292)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU746877B2 (en) * | 1997-07-31 | 2002-05-02 | Procter & Gamble Company, The | Acyclic metalloprotease inhibitors |
PA8469301A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Procedimientos para la preparacion de acidos hidroxamicos. |
GT199900044A (es) * | 1998-04-10 | 2000-09-14 | Procedimientos para preparar haluros de fenoxifenilsulfonilo. | |
PA8469601A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Procedimiento para alquilar sulfonamidas impedidas estericamente |
UA59453C2 (uk) * | 1998-08-12 | 2003-09-15 | Пфайзер Продактс Інк. | Похідні гідроксипіпеколат гідроксамової кислоти як інгібітори матричних металопротеїназ |
US6762178B2 (en) | 1999-01-27 | 2004-07-13 | Wyeth Holdings Corporation | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors |
US6200996B1 (en) | 1999-01-27 | 2001-03-13 | American Cyanamid Company | Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors |
US6340691B1 (en) | 1999-01-27 | 2002-01-22 | American Cyanamid Company | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors |
US6225311B1 (en) | 1999-01-27 | 2001-05-01 | American Cyanamid Company | Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors |
US6313123B1 (en) | 1999-01-27 | 2001-11-06 | American Cyanamid Company | Acetylenic sulfonamide thiol tace inhibitors |
US6753337B2 (en) | 1999-01-27 | 2004-06-22 | Wyeth Holdings Corporation | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors |
US6946473B2 (en) | 1999-01-27 | 2005-09-20 | Wyeth Holdings Corporation | Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors |
US6277885B1 (en) | 1999-01-27 | 2001-08-21 | American Cyanamid Company | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors |
US6326516B1 (en) | 1999-01-27 | 2001-12-04 | American Cyanamid Company | Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors |
EP1147085B1 (en) | 1999-01-27 | 2005-11-16 | Wyeth Holdings Corporation | Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (mmp) inhibitors / tnf-alpha converting enzyme (tace) inhibitors |
JP2002538136A (ja) | 1999-03-03 | 2002-11-12 | ザ プロクター アンド ギャンブル カンパニー | アルケニルおよびアルキニル含有メタロプロテアーゼ阻害剤 |
US6566381B1 (en) | 1999-03-03 | 2003-05-20 | The Procter & Gamble Company | Hetero-substituted metalloprotease inhibitors |
WO2000058280A1 (fr) * | 1999-03-26 | 2000-10-05 | Shionogi & Co., Ltd. | Derives de sulfonamide carbocyclique |
DE60003863T2 (de) | 1999-03-31 | 2004-04-22 | Pfizer Products Inc., Groton | Dioxocyclopentylhydroxamsäure |
DE60006523T2 (de) | 1999-05-28 | 2004-08-12 | Pfizer Products Inc., Groton | `3-(arylsulfonylamino)-tetrahydropyran-3-carbonsäure hydroxamide |
HN2000000052A (es) * | 1999-05-28 | 2001-02-02 | Pfizer Prod Inc | Hidroxiamidas de acidos 3- (arilsulfonilamino)- tetrahidrofuran-3-carboxilicos. |
GB9918684D0 (en) * | 1999-08-09 | 1999-10-13 | Novartis Ag | Organic compounds |
IL138686A0 (en) * | 1999-10-01 | 2001-10-31 | Pfizer Prod Inc | α- SULFONYLAMINO HYDROXAMIC ACID INHIBITORS OF MATRIX METALLOPROTEINASES FOR THE TREATMENT OF PERIPHERAL OR CENTRAL NERVOUS SYSTEM DISORDERS |
UA74803C2 (uk) | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування |
US7141607B1 (en) | 2000-03-10 | 2006-11-28 | Insite Vision Incorporated | Methods and compositions for treating and inhibiting retinal neovascularization |
WO2001070691A1 (en) | 2000-03-21 | 2001-09-27 | The Procter & Gamble Company | Heterocyclic side chain containing, n-substituted metalloprotease inhibitors |
IL151124A0 (en) * | 2000-03-21 | 2003-04-10 | Procter & Gamble | Heterocyclic side chain containing metalloprotease inhibitors |
AU2001245862A1 (en) | 2000-03-21 | 2001-10-03 | The Procter & Gamble Company | Difluorobutyric acid metalloprotease inhibitors |
AU2001290131B2 (en) * | 2000-09-29 | 2007-11-15 | Topotarget Uk Limited | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors |
EP1348443A4 (en) * | 2000-12-08 | 2005-07-06 | Takeda Pharmaceutical | COMBINED MEDICINES |
CA2433800C (en) | 2001-01-05 | 2016-09-13 | Pfizer Inc. | Antibodies to insulin-like growth factor i receptor |
GB0103303D0 (en) | 2001-02-09 | 2001-03-28 | Novartis Ag | Organic compounds |
WO2003000194A2 (en) | 2001-06-21 | 2003-01-03 | Pfizer Inc. | Thienopyridine and thienopyrimidine anticancer agents |
JP2005507937A (ja) | 2001-11-01 | 2005-03-24 | ワイス・ホールディングズ・コーポレイション | マトリックスメタロプロテイナーゼおよびtace阻害剤としてのアレンアリールスルホンアミドヒドロキサム酸 |
AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
AU2002361096A1 (en) * | 2001-12-27 | 2003-07-15 | Sumitomo Pharmaceuticals Company, Limited | Hydroxamic acid derivative and mmp inhibitor containing the same as active ingredient |
CA2472578A1 (en) * | 2002-01-24 | 2003-07-31 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Anti-cancer combination and use thereof |
DE10206404A1 (de) * | 2002-02-14 | 2003-08-28 | Gruenenthal Gmbh | Synthese von substituierten Sulfonylaminen |
BR0308162A (pt) | 2002-03-01 | 2004-12-07 | Pfizer | Derivados de indolil-uréia de tienopiridinas úteis como agentes antiangiogênicos e métodos para o seu uso |
PL401637A1 (pl) | 2002-03-13 | 2013-05-27 | Array Biopharma Inc. | N3 alkilowane pochodne benzimidazolu jako inhibitory MEK |
UA77303C2 (en) | 2002-06-14 | 2006-11-15 | Pfizer | Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use |
PL377713A1 (pl) | 2002-12-19 | 2006-02-06 | Pfizer Inc. | Związki 2-(1H-indazol-6-iloamino)benzamidowe jako inhibitory kinaz białkowych użyteczne w leczeniu chorób oczu |
AU2003304456A1 (en) | 2002-12-23 | 2005-03-16 | Wyeth Holdings Corporation | Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors |
JP2006517216A (ja) * | 2003-02-11 | 2006-07-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗コリン作用剤とtace阻害剤に基づく新規な医薬組成物 |
AP2114A (en) | 2003-02-26 | 2010-03-04 | Sugen Inc | Aminoheteroaryl compounds as protein kinase inhibitors |
ATE412655T1 (de) | 2003-08-29 | 2008-11-15 | Pfizer | Als neue antiangiogene mittel geeignete thienopyridinphenylacetamide und derivate davon |
US7144907B2 (en) | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
WO2005051302A2 (en) | 2003-11-19 | 2005-06-09 | Array Biopharma Inc. | Bicyclic inhibitors of mek and methods of use thereof |
DE602004028150D1 (de) * | 2003-11-26 | 2010-08-26 | Pfizer Prod Inc | Aminopyrazolderivate als gsk-3-inhibitoren |
ITFI20040174A1 (it) * | 2004-08-03 | 2004-11-03 | Protera S R L | Derivati arilsolfonammidici dell'acido idrossammico ad azione inibitoria di metalloproteinasi |
DK1786785T3 (da) | 2004-08-26 | 2010-05-31 | Pfizer | Enantiomerisk rene aminoheteroaryl-forbindelser som proteinkinasehæmmere |
MY146381A (en) | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
US7429667B2 (en) | 2005-01-20 | 2008-09-30 | Ardea Biosciences, Inc. | Phenylamino isothiazole carboxamidines as MEK inhibitors |
KR20080019236A (ko) | 2005-05-18 | 2008-03-03 | 어레이 바이오파마 인크. | Mek의 헤테로시클릭 억제제 및 그의 사용 방법 |
US8101799B2 (en) | 2005-07-21 | 2012-01-24 | Ardea Biosciences | Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK |
AU2006292278B2 (en) | 2005-09-20 | 2012-03-08 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
TWI405756B (zh) | 2005-12-21 | 2013-08-21 | Array Biopharma Inc | 新穎硫酸氫鹽 |
KR20080104347A (ko) * | 2006-03-29 | 2008-12-02 | 노파르티스 아게 | 선택적 히드록사메이트-기재 mmp 억제제 |
WO2007121269A2 (en) | 2006-04-11 | 2007-10-25 | Ardea Biosciences, Inc. | N-aryl-n'alkyl sulfamides as mek inhibitors |
ATE483463T1 (de) | 2006-04-18 | 2010-10-15 | Ardea Biosciences Inc | Pyridonsulfonamide und pyridonsulfamide als mek- hemmer |
JP2010513263A (ja) | 2006-12-15 | 2010-04-30 | ファイザー・プロダクツ・インク | ベンズイミダゾール誘導体 |
JP5491199B2 (ja) | 2007-01-19 | 2014-05-14 | アルデア バイオサイエンシズ,インコーポレイティド | Mekのインヒビター |
WO2008129380A1 (en) | 2007-04-18 | 2008-10-30 | Pfizer Products Inc. | Sulfonyl amide derivatives for the treatment of abnormal cell growth |
US8530463B2 (en) | 2007-05-07 | 2013-09-10 | Hale Biopharma Ventures Llc | Multimodal particulate formulations |
TWI446905B (zh) * | 2007-06-05 | 2014-08-01 | Sanofi Aventis | 經取代之苯甲醯基胺基-氫茚-2-羧酸及相關化合物 |
CA2694646C (en) | 2007-07-30 | 2017-09-05 | Ardea Biosciences, Inc. | Combinations of mek inhibitors and raf kinase inhibitors and uses thereof |
CN101945870B (zh) | 2007-12-19 | 2012-10-03 | 健泰科生物技术公司 | 5-苯氨基咪唑并吡啶和使用方法 |
CN101945875B (zh) | 2007-12-21 | 2013-04-24 | 健泰科生物技术公司 | 氮杂吲嗪及其使用方法 |
EP3613743B1 (en) | 2008-01-04 | 2022-03-16 | Intellikine, LLC | Processes for the preparation of 1h-pyrazolo[3,4-d]pyrimidin-4-amine derivatives |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
US8637542B2 (en) | 2008-03-14 | 2014-01-28 | Intellikine, Inc. | Kinase inhibitors and methods of use |
CA2756690C (en) | 2008-03-28 | 2016-08-16 | Hale Biopharma Ventures, Llc | Administration of benzodiazepine compositions |
CN102124009B (zh) | 2008-07-08 | 2014-07-23 | 因特利凯公司 | 激酶抑制剂及其使用方法 |
US8476410B2 (en) | 2008-10-16 | 2013-07-02 | University of Pittsburgh—of the Commonwealth System of Higher Education | Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof |
US8476431B2 (en) | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
JP5977522B2 (ja) | 2009-02-05 | 2016-08-24 | イミュノジェン・インコーポレーテッド | 新規ベンゾジアゼピン誘導体 |
AU2010210986A1 (en) | 2009-02-09 | 2011-08-25 | Supergen, Inc. | Pyrrolopyrimidinyl Axl kinase inhibitors |
EP2400985A2 (en) | 2009-02-25 | 2012-01-04 | OSI Pharmaceuticals, LLC | Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor |
EP2400990A2 (en) | 2009-02-26 | 2012-01-04 | OSI Pharmaceuticals, LLC | In situ methods for monitoring the emt status of tumor cells in vivo |
TW201035088A (en) | 2009-02-27 | 2010-10-01 | Supergen Inc | Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors |
EP2401614A1 (en) | 2009-02-27 | 2012-01-04 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
US8465912B2 (en) | 2009-02-27 | 2013-06-18 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
CA2756566A1 (en) | 2009-03-27 | 2010-09-30 | Ardea Biosciences, Inc. | Dihydropyridin sulfonamides as mek inhibitors |
CA2760791C (en) | 2009-05-07 | 2017-06-20 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
US20120128670A1 (en) | 2009-07-31 | 2012-05-24 | OSI Pharmaceuticals, LLC | mTOR INHIBITOR AND ANGIOGENESIS INHIBITOR COMBINATION THERAPY |
EP2467141B1 (en) | 2009-08-17 | 2018-10-31 | Intellikine, LLC | Heterocyclic compounds and uses thereof |
WO2011027249A2 (en) | 2009-09-01 | 2011-03-10 | Pfizer Inc. | Benzimidazole derivatives |
WO2011047055A2 (en) | 2009-10-13 | 2011-04-21 | Allostem Therapeutics Llc | Novel mek inhibitors, useful in the treatment of diseases |
WO2011049625A1 (en) | 2009-10-20 | 2011-04-28 | Mansour Samadpour | Method for aflatoxin screening of products |
EA027123B1 (ru) | 2009-11-05 | 2017-06-30 | Ризен Фармасьютикалз С.А. | Ингибиторы киназы pi3k |
JP5841072B2 (ja) | 2010-02-10 | 2016-01-06 | イミュノジェン・インコーポレーテッド | Cd20抗体およびその使用 |
ES2753748T3 (es) | 2010-02-12 | 2020-04-14 | Pfizer | Sales y polimorfos de 8-fluoro-2-{4-[(metilamino}metil]fenil}-1,3,4,5-tetrahidro-6H-azepino[5,4,3-cd]indol-6-ona |
CA2783656A1 (en) | 2010-03-03 | 2011-09-09 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
EP2542893A2 (en) | 2010-03-03 | 2013-01-09 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
EP2571878B1 (en) | 2010-05-17 | 2018-10-17 | Incozen Therapeutics Pvt. Ltd. | Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b]pyridine compounds as modulators of protein kinases |
US8604032B2 (en) | 2010-05-21 | 2013-12-10 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
CN103068851B (zh) | 2010-06-16 | 2015-03-11 | 高等教育联邦***-匹兹堡大学 | 内质蛋白的抗体及其用途 |
FR2962649A1 (fr) | 2010-07-19 | 2012-01-20 | Conservatoire Nat Arts Et Metiers | Traitement d'une pathologie liee a un effet excessif du tnf par un compose de benzene sulfonamide |
WO2012052948A1 (en) | 2010-10-20 | 2012-04-26 | Pfizer Inc. | Pyridine- 2- derivatives as smoothened receptor modulators |
WO2012064973A2 (en) | 2010-11-10 | 2012-05-18 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
TWI674262B (zh) | 2011-01-10 | 2019-10-11 | 美商英菲尼提製藥股份有限公司 | 製備異喹啉酮之方法及異喹啉酮之固體形式 |
US20140037642A1 (en) | 2011-02-02 | 2014-02-06 | Amgen Inc. | Methods and compositions relating to inhibition of igf-1r |
SG10201601046QA (en) | 2011-02-15 | 2016-03-30 | Immunogen Inc | Cytotoxic benzodiazepine derivatives |
US20120214830A1 (en) | 2011-02-22 | 2012-08-23 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma |
EP2678016B1 (en) | 2011-02-23 | 2016-08-10 | Intellikine, LLC | Heterocyclic compounds and uses thereof |
US9150644B2 (en) | 2011-04-12 | 2015-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II |
DK2699598T3 (en) | 2011-04-19 | 2019-04-23 | Pfizer | COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INducing ANTIBODIES FOR TREATMENT OF CANCER |
WO2012149014A1 (en) | 2011-04-25 | 2012-11-01 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
CN107337659A (zh) | 2011-05-04 | 2017-11-10 | 理森制药股份公司 | 作为蛋白激酶调节剂的新颖化合物 |
EP3415139B8 (en) | 2011-06-14 | 2022-05-18 | Neurelis, Inc. | Administration of benzodiazepine |
KR20140063605A (ko) | 2011-07-19 | 2014-05-27 | 인피니티 파마슈티칼스, 인코포레이티드 | 헤테로사이클릭 화합물 및 그의 용도 |
AU2012284088B2 (en) | 2011-07-19 | 2015-10-08 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
EP3812387A1 (en) | 2011-07-21 | 2021-04-28 | Sumitomo Dainippon Pharma Oncology, Inc. | Heterocyclic protein kinase inhibitors |
RU2014111823A (ru) | 2011-08-29 | 2015-10-10 | Инфинити Фармасьютикалз, Инк. | Гетероциклические соединения и их применения |
CA2847540C (en) | 2011-09-22 | 2016-05-17 | Pfizer Inc. | Pyrrolopyrimidine and purine derivatives |
WO2013049332A1 (en) | 2011-09-29 | 2013-04-04 | Infinity Pharmaceuticals, Inc. | Inhibitors of monoacylglycerol lipase and methods of their use |
EP3275902A1 (en) | 2011-10-04 | 2018-01-31 | IGEM Therapeutics Limited | Ige anti-hmw-maa antibody |
AU2012335247A1 (en) | 2011-11-08 | 2014-05-29 | Pfizer Inc. | Methods of treating inflammatory disorders using anti-M-CSF antibodies |
EP2817004B1 (en) | 2012-02-22 | 2018-04-11 | The Regents of The University of Colorado, A Body Corporate | Bouvardin derivatives and therapeutic uses thereof |
US9452215B2 (en) | 2012-02-22 | 2016-09-27 | The Regents Of The University Of Colorado | Bourvadin derivatives and therapeutic uses thereof |
AP3908A (en) | 2012-03-30 | 2016-11-24 | Rhizen Pharmaceuticals Sa | Novel 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo [4,5-B] pyridine compounds as modulators of C-met protein kinases |
WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
EP2859017B1 (en) | 2012-06-08 | 2019-02-20 | Sutro Biopharma, Inc. | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
US9732161B2 (en) | 2012-06-26 | 2017-08-15 | Sutro Biopharma, Inc. | Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use |
WO2014031566A1 (en) | 2012-08-22 | 2014-02-27 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives |
KR102182800B1 (ko) | 2012-08-31 | 2020-11-25 | 서트로 바이오파마, 인크. | 아지도 기를 포함하는 변형된 아미노산 |
EP2909181B1 (en) | 2012-10-16 | 2017-08-09 | Tolero Pharmaceuticals, Inc. | Pkm2 modulators and methods for their use |
NZ744567A (en) | 2012-11-01 | 2020-03-27 | Infinity Pharmaceuticals Inc | Treatment of cancers using pi3 kinase isoform modulators |
US9901647B2 (en) | 2013-02-28 | 2018-02-27 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
EP2961434A2 (en) | 2013-02-28 | 2016-01-06 | ImmunoGen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
EP2970205B1 (en) | 2013-03-14 | 2019-05-08 | Tolero Pharmaceuticals, Inc. | Jak2 and alk2 inhibitors and methods for their use |
TW201524952A (zh) | 2013-03-15 | 2015-07-01 | Araxes Pharma Llc | Kras g12c之共價抑制劑 |
NZ629037A (en) | 2013-03-15 | 2017-04-28 | Infinity Pharmaceuticals Inc | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
US9745319B2 (en) | 2013-03-15 | 2017-08-29 | Araxes Pharma Llc | Irreversible covalent inhibitors of the GTPase K-Ras G12C |
UY35464A (es) | 2013-03-15 | 2014-10-31 | Araxes Pharma Llc | Inhibidores covalentes de kras g12c. |
CN105246482A (zh) | 2013-03-15 | 2016-01-13 | 因特利凯有限责任公司 | 激酶抑制剂的组合及其用途 |
RU2019134551A (ru) | 2013-05-30 | 2019-11-22 | Инфинити Фармасьютикалз, Инк. | Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы |
WO2014194030A2 (en) | 2013-05-31 | 2014-12-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
US9764039B2 (en) | 2013-07-10 | 2017-09-19 | Sutro Biopharma, Inc. | Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
PT3052096T (pt) | 2013-10-03 | 2018-04-04 | Kura Oncology Inc | Inibidores de erk e métodos de utilização |
WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
HUE057734T2 (hu) | 2013-10-04 | 2022-06-28 | Infinity Pharmaceuticals Inc | Heterociklusos vegyületek és alkalmazásuk |
JO3805B1 (ar) | 2013-10-10 | 2021-01-31 | Araxes Pharma Llc | مثبطات كراس جي12سي |
JP6559123B2 (ja) | 2013-10-10 | 2019-08-14 | アラクセス ファーマ エルエルシー | Krasg12cの阻害剤 |
US9840493B2 (en) | 2013-10-11 | 2017-12-12 | Sutro Biopharma, Inc. | Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use |
US20160244452A1 (en) | 2013-10-21 | 2016-08-25 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
UA115388C2 (uk) | 2013-11-21 | 2017-10-25 | Пфайзер Інк. | 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань |
WO2015155624A1 (en) | 2014-04-10 | 2015-10-15 | Pfizer Inc. | Dihydropyrrolopyrimidine derivatives |
WO2015168079A1 (en) | 2014-04-29 | 2015-11-05 | Infinity Pharmaceuticals, Inc. | Pyrimidine or pyridine derivatives useful as pi3k inhibitors |
MX2016014143A (es) | 2014-04-30 | 2017-02-15 | Pfizer | Derivados de diheterociclo enlazado a cicloalquilo. |
CA2949793C (en) | 2014-06-19 | 2024-02-27 | Ariad Pharmaceuticals, Inc. | Heteroaryl compounds for kinase inhibition |
WO2016001789A1 (en) | 2014-06-30 | 2016-01-07 | Pfizer Inc. | Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer |
CN106999578B (zh) | 2014-07-31 | 2022-03-04 | 美国政府(由卫生和人类服务部的部长所代表) | 针对epha4的人类单克隆抗体和其用途 |
JO3556B1 (ar) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
WO2016049568A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Methods and compositions for inhibition of ras |
ES2826443T3 (es) | 2014-09-25 | 2021-05-18 | Araxes Pharma Llc | Inhibidores de proteínas mutantes KRAS G12C |
JP6621477B2 (ja) | 2014-12-18 | 2019-12-18 | ファイザー・インク | ピリミジンおよびトリアジン誘導体ならびにaxl阻害薬としてのそれらの使用 |
TW201702232A (zh) | 2015-04-10 | 2017-01-16 | 亞瑞克西斯製藥公司 | 經取代之喹唑啉化合物及其使用方法 |
CA2982360A1 (en) | 2015-04-15 | 2016-10-20 | Liansheng Li | Fused-tricyclic inhibitors of kras and methods of use thereof |
KR20180018507A (ko) | 2015-04-20 | 2018-02-21 | 톨레로 파마수티컬스, 인크. | 미토콘드리아 프로파일링에 의한 알보시딥에 대한 반응 예측 |
WO2016178876A2 (en) | 2015-05-01 | 2016-11-10 | Cocrystal Pharma, Inc. | Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer |
MX2017014645A (es) | 2015-05-18 | 2018-01-23 | Tolero Pharmaceuticals Inc | Profarmacos de alvocidib que tienen una biodisponibilidad aumentada. |
AR104020A1 (es) | 2015-06-04 | 2017-06-21 | Kura Oncology Inc | Métodos y composiciones para inhibir la interacción de menina con proteínas mill |
WO2017009751A1 (en) | 2015-07-15 | 2017-01-19 | Pfizer Inc. | Pyrimidine derivatives |
US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
WO2017024073A1 (en) | 2015-08-03 | 2017-02-09 | Tolero Pharmaceuticals, Inc. | Combination therapies for treatment of cancer |
US10975071B2 (en) | 2015-09-28 | 2021-04-13 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
EP3356339A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
WO2017058805A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
WO2017058768A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
US10875842B2 (en) | 2015-09-28 | 2020-12-29 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
WO2017058728A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
WO2017058792A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
WO2017070256A2 (en) | 2015-10-19 | 2017-04-27 | Araxes Pharma Llc | Method for screening inhibitors of ras |
TW201726656A (zh) | 2015-11-16 | 2017-08-01 | 亞瑞克西斯製藥公司 | 包含經取代雜環基團之2-經取代喹唑啉化合物及其使用方法 |
KR20180100125A (ko) | 2015-12-03 | 2018-09-07 | 아지오스 파마슈티컬스 아이엔씨. | Mtap 널 암을 치료하기 위한 mat2a 억제제 |
WO2017100546A1 (en) | 2015-12-09 | 2017-06-15 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
KR20180104106A (ko) | 2016-01-27 | 2018-09-19 | 서트로 바이오파마, 인크. | anti-CD74 항체 접합체, anti-CD74 항체 접합체를 포함하는 조성물 및 anti-CD74 항체 접합체의 이용 방법 |
ES2695533T3 (es) | 2016-02-01 | 2019-01-08 | Galderma Res & Dev | Compuestos de bencenosulfonamida, método para su síntesis y uso de los mismos en medicina y cosméticos |
RS64261B1 (sr) | 2016-03-16 | 2023-07-31 | Kura Oncology Inc | Supstituisani derivati tieno[2,3-d]pirimidina kao inhibitori menin-mll i načini upotrebe |
BR112018068702A2 (pt) | 2016-03-16 | 2019-01-15 | Kura Oncology Inc | inibidores bicíclicos em ponte de menin-mll e métodos de uso |
WO2017172979A1 (en) | 2016-03-30 | 2017-10-05 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
JP2019516700A (ja) | 2016-05-12 | 2019-06-20 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | Ash1l阻害剤及びそれを用いた治療方法 |
WO2017201302A1 (en) | 2016-05-18 | 2017-11-23 | The University Of Chicago | Btk mutation and ibrutinib resistance |
WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
AU2017321973A1 (en) | 2016-09-02 | 2019-03-07 | Dana-Farber Cancer Institute, Inc. | Composition and methods of treating B cell disorders |
WO2018064510A1 (en) | 2016-09-29 | 2018-04-05 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
WO2018068017A1 (en) | 2016-10-07 | 2018-04-12 | Araxes Pharma Llc | Heterocyclic compounds as inhibitors of ras and methods of use thereof |
WO2018094275A1 (en) | 2016-11-18 | 2018-05-24 | Tolero Pharmaceuticals, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
WO2018098352A2 (en) | 2016-11-22 | 2018-05-31 | Jun Oishi | Targeting kras induced immune checkpoint expression |
CN110234659A (zh) | 2016-12-19 | 2019-09-13 | 特雷罗药物股份有限公司 | 用于敏感性分析的分析肽和方法 |
MA47107B1 (fr) | 2016-12-22 | 2021-11-30 | Amgen Inc | Dérivés de benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine et pyrido[2,3-d]pyrimidine en tant qu'inhibiteurs de kras g12c pour le traitement de cancer du poumon, du pancréas ou de l'intestin |
CN110461872B (zh) | 2017-01-26 | 2023-09-26 | 再鼎医药(上海)有限公司 | Cd47抗原结合单元及其用途 |
JP7327802B2 (ja) | 2017-01-26 | 2023-08-16 | アラクセス ファーマ エルエルシー | 縮合ヘテロ-ヘテロ二環式化合物およびその使用方法 |
US11274093B2 (en) | 2017-01-26 | 2022-03-15 | Araxes Pharma Llc | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
US20200385364A1 (en) | 2017-01-26 | 2020-12-10 | Araxes Pharma Llc | Fused n-heterocyclic compounds and methods of use thereof |
EP3573964A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Benzothiophene and benzothiazole compounds and methods of use thereof |
EP3573970A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer |
US11279689B2 (en) | 2017-01-26 | 2022-03-22 | Araxes Pharma Llc | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer |
US11944627B2 (en) | 2017-03-24 | 2024-04-02 | Kura Oncology, Inc. | Methods for treating hematological malignancies and Ewing's sarcoma |
JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
BR112019024674A2 (pt) | 2017-05-25 | 2020-06-16 | Araxes Pharma Llc | Inibidores covalentes da kras |
EP3630747A1 (en) | 2017-05-25 | 2020-04-08 | Araxes Pharma LLC | Quinazoline derivatives as modulators of mutant kras, hras or nras |
JP2020521741A (ja) | 2017-05-25 | 2020-07-27 | アラクセス ファーマ エルエルシー | がんの処置のための化合物およびその使用の方法 |
US11542248B2 (en) | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
EP3658588A1 (en) | 2017-07-26 | 2020-06-03 | Sutro Biopharma, Inc. | Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma |
IL272512B (en) | 2017-09-08 | 2022-07-01 | Amgen Inc | kras g12c inhibitors and methods of using them |
US11497756B2 (en) | 2017-09-12 | 2022-11-15 | Sumitomo Pharma Oncology, Inc. | Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib |
EP3684814A1 (en) | 2017-09-18 | 2020-07-29 | Sutro Biopharma, Inc. | Anti-folate receptor alpha antibody conjugates and their uses |
TW201920170A (zh) | 2017-09-20 | 2019-06-01 | 美商庫拉腫瘤技術股份有限公司 | 經取代之menin-mll 抑制劑及使用方法 |
US20200237766A1 (en) | 2017-10-13 | 2020-07-30 | Tolero Pharmaceuticals, Inc. | Pkm2 activators in combination with reactive oxygen species for treatment of cancer |
JP7424637B2 (ja) | 2017-11-10 | 2024-01-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | Ash1l分解剤及びそれを用いた治療方法 |
JP7414282B2 (ja) | 2017-12-07 | 2024-01-16 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | Nsdファミリー阻害物質及びそれによる治療の方法 |
BR112020020246A8 (pt) | 2018-04-05 | 2022-10-18 | Sumitomo Dainippon Pharma Oncology Inc | Inibidores de cinase axl e uso dos mesmos |
CA3098574A1 (en) | 2018-05-04 | 2019-11-07 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
MX2020011582A (es) | 2018-05-04 | 2020-11-24 | Amgen Inc | Inhibidores de kras g12c y metodos para su uso. |
US10988485B2 (en) | 2018-05-10 | 2021-04-27 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
ES2938987T3 (es) | 2018-06-01 | 2023-04-18 | Amgen Inc | Inhibidores de KRAS G12c y métodos de uso de los mismos |
CN112533581A (zh) | 2018-06-07 | 2021-03-19 | 密歇根大学董事会 | Prc1抑制剂及用其进行治疗的方法 |
US20190375749A1 (en) | 2018-06-11 | 2019-12-12 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
US11285156B2 (en) | 2018-06-12 | 2022-03-29 | Amgen Inc. | Substituted piperazines as KRAS G12C inhibitors |
CN112512597A (zh) | 2018-07-26 | 2021-03-16 | 大日本住友制药肿瘤公司 | 用于治疗与acvr1表达异常相关的疾病的方法以及用于此的acvr1抑制剂 |
WO2020028706A1 (en) | 2018-08-01 | 2020-02-06 | Araxes Pharma Llc | Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer |
EP3852811A1 (en) | 2018-09-17 | 2021-07-28 | Sutro Biopharma, Inc. | Combination therapies with anti-folate receptor antibody conjugates |
CN113207291A (zh) | 2018-10-24 | 2021-08-03 | 亚瑞克西斯制药公司 | 2-(2-丙烯酰基-2,6-二氮杂螺[3.4]辛-6-基)-6-(1h-吲唑-4-基)苄腈衍生物及相关化合物作为用于抑制肿瘤转移的g12c突变kras蛋白的抑制剂 |
JP2020090482A (ja) | 2018-11-16 | 2020-06-11 | アムジエン・インコーポレーテツド | Kras g12c阻害剤化合物の重要な中間体の改良合成法 |
WO2020106640A1 (en) | 2018-11-19 | 2020-05-28 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法 |
MX2021005924A (es) | 2018-11-29 | 2021-06-30 | Araxes Pharma Llc | Compuestos y metodos de uso de los mismos para el tratamiento del cancer. |
CA3119807A1 (en) | 2018-12-04 | 2020-06-11 | Sumitomo Dainippon Pharma Oncology, Inc. | Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer |
CA3123871A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Kif18a inhibitors |
WO2020132651A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Kif18a inhibitors |
EP3898592A1 (en) | 2018-12-20 | 2021-10-27 | Amgen Inc. | Heteroaryl amides useful as kif18a inhibitors |
MX2021007158A (es) | 2018-12-20 | 2021-08-16 | Amgen Inc | Heteroarilamidas utiles como inhibidores de kif18a. |
CA3127502A1 (en) | 2019-02-12 | 2020-08-20 | Sumitomo Dainippon Pharma Oncology, Inc. | Formulations comprising heterocyclic protein kinase inhibitors |
WO2020180768A1 (en) | 2019-03-01 | 2020-09-10 | Revolution Medicines, Inc. | Bicyclic heteroaryl compounds and uses thereof |
KR20210146288A (ko) | 2019-03-01 | 2021-12-03 | 레볼루션 메디슨즈, 인크. | 이환식 헤테로사이클릴 화합물 및 이의 용도 |
JP2022525149A (ja) | 2019-03-20 | 2022-05-11 | スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド | ベネトクラクスが失敗した急性骨髄性白血病(aml)の処置 |
KR20210141621A (ko) | 2019-03-22 | 2021-11-23 | 스미토모 다이니폰 파마 온콜로지, 인크. | Pkm2 조정제를 포함하는 조성물 및 그를 사용한 치료 방법 |
WO2020227105A1 (en) | 2019-05-03 | 2020-11-12 | Sutro Biopharma, Inc. | Anti-bcma antibody conjugates |
EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
BR112021023277A2 (pt) | 2019-05-21 | 2022-01-04 | Amgen Inc | Formas em estado sólido |
JP2022539208A (ja) | 2019-07-03 | 2022-09-07 | スミトモ ファーマ オンコロジー, インコーポレイテッド | チロシンキナーゼ非受容体1(tnk1)阻害剤およびその使用 |
AU2020324406A1 (en) | 2019-08-02 | 2022-03-17 | Amgen Inc. | KIF18A inhibitors |
JP2022542394A (ja) | 2019-08-02 | 2022-10-03 | アムジエン・インコーポレーテツド | Kif18a阻害剤として有用なヘテロアリールアミド |
CA3146693A1 (en) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Kif18a inhibitors |
AU2020325115A1 (en) | 2019-08-02 | 2022-03-17 | Amgen Inc. | Pyridine derivatives as KIF18A inhibitors |
WO2021067215A1 (en) | 2019-09-30 | 2021-04-08 | Agios Pharmaceuticals, Inc. | Piperidine compounds as menin inhibitors |
MX2022004656A (es) | 2019-10-24 | 2022-05-25 | Amgen Inc | Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer. |
WO2021086833A1 (en) | 2019-10-28 | 2021-05-06 | Merck Sharp & Dohme Corp. | Small molecule inhibitors of kras g12c mutant |
CN115551500A (zh) | 2019-10-31 | 2022-12-30 | 大鹏药品工业株式会社 | 4-氨基丁-2-烯酰胺衍生物及其盐 |
CN114867735A (zh) | 2019-11-04 | 2022-08-05 | 锐新医药公司 | Ras抑制剂 |
AU2020379734A1 (en) | 2019-11-04 | 2022-05-05 | Revolution Medicines, Inc. | Ras inhibitors |
TW202132315A (zh) | 2019-11-04 | 2021-09-01 | 美商銳新醫藥公司 | Ras 抑制劑 |
CN114901662A (zh) | 2019-11-08 | 2022-08-12 | 锐新医药公司 | 双环杂芳基化合物及其用途 |
AR120456A1 (es) | 2019-11-14 | 2022-02-16 | Amgen Inc | Síntesis mejorada del compuesto inhibidor de g12c de kras |
US20230192681A1 (en) | 2019-11-14 | 2023-06-22 | Amgen Inc. | Improved synthesis of kras g12c inhibitor compound |
CN114980976A (zh) | 2019-11-27 | 2022-08-30 | 锐新医药公司 | 共价ras抑制剂及其用途 |
WO2021106231A1 (en) | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
CA3163703A1 (en) | 2020-01-07 | 2021-07-15 | Steve Kelsey | Shp2 inhibitor dosing and methods of treating cancer |
WO2021155006A1 (en) | 2020-01-31 | 2021-08-05 | Les Laboratoires Servier Sas | Inhibitors of cyclin-dependent kinases and uses thereof |
WO2021178597A1 (en) | 2020-03-03 | 2021-09-10 | Sutro Biopharma, Inc. | Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use |
WO2021207310A1 (en) | 2020-04-08 | 2021-10-14 | Agios Pharmaceuticals, Inc. | Menin inhibitors and methods of use for treating cancer |
TW202204333A (zh) | 2020-04-08 | 2022-02-01 | 美商阿吉歐斯製藥公司 | Menin抑制劑及治療癌症之使用方法 |
WO2021215544A1 (en) | 2020-04-24 | 2021-10-28 | Taiho Pharmaceutical Co., Ltd. | Kras g12d protein inhibitors |
US20230181536A1 (en) | 2020-04-24 | 2023-06-15 | Taiho Pharmaceutical Co., Ltd. | Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c |
CN115916194A (zh) | 2020-06-18 | 2023-04-04 | 锐新医药公司 | 用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法 |
CA3185209A1 (en) | 2020-07-10 | 2021-01-27 | Alyssa WINKLER | Gas41 inhibitors and methods of use thereof |
JP7373664B2 (ja) | 2020-07-15 | 2023-11-02 | 大鵬薬品工業株式会社 | 腫瘍の治療に使用されるピリミジン化合物を含む組み合わせ |
CN116209438A (zh) | 2020-09-03 | 2023-06-02 | 锐新医药公司 | 使用sos1抑制剂治疗具有shp2突变的恶性疾病 |
CN116457358A (zh) | 2020-09-15 | 2023-07-18 | 锐新医药公司 | 作为ras抑制剂以治疗癌症的吲哚衍生物 |
TW202237119A (zh) | 2020-12-10 | 2022-10-01 | 美商住友製藥腫瘤公司 | Alk﹘5抑制劑和彼之用途 |
TW202241885A (zh) | 2020-12-22 | 2022-11-01 | 大陸商上海齊魯銳格醫藥研發有限公司 | Sos1抑制劑及其用途 |
KR20230170039A (ko) | 2021-04-13 | 2023-12-18 | 뉴베일런트, 아이엔씨. | Egfr 돌연변이를 지니는 암을 치료하기 위한 아미노-치환된 헤테로사이클 |
KR20240004659A (ko) | 2021-04-30 | 2024-01-11 | 셀진 코포레이션 | 감마 세크레타제 억제제(gsi)와 병용하여 항-bcma 항체-약물 접합체(adc)를 사용하는 병용 요법 |
TW202309052A (zh) | 2021-05-05 | 2023-03-01 | 美商銳新醫藥公司 | Ras抑制劑 |
WO2022235866A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
IL308195A (en) | 2021-05-05 | 2024-01-01 | Revolution Medicines Inc | RAS inhibitors for cancer treatment |
EP4347041A1 (en) | 2021-05-28 | 2024-04-10 | Taiho Pharmaceutical Co., Ltd. | Small molecule inhibitors of kras mutated proteins |
AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
WO2023056589A1 (en) | 2021-10-08 | 2023-04-13 | Servier Pharmaceuticals Llc | Menin inhibitors and methods of use for treating cancer |
WO2023114954A1 (en) | 2021-12-17 | 2023-06-22 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
WO2023211812A1 (en) | 2022-04-25 | 2023-11-02 | Nested Therapeutics, Inc. | Heterocyclic derivatives as mitogen-activated protein kinase (mek) inhibitors |
WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
US20240058465A1 (en) | 2022-06-30 | 2024-02-22 | Sutro Biopharma, Inc. | Anti-ror1 antibody conjugates, compositions comprising anti ror1 antibody conjugates, and methods of making and using anti-ror1 antibody conjugates |
WO2024010925A2 (en) | 2022-07-08 | 2024-01-11 | Nested Therapeutics, Inc. | Mitogen-activated protein kinase (mek) inhibitors |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5455258A (en) * | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
WO1996000214A1 (en) * | 1994-06-24 | 1996-01-04 | Ciba-Geigy Ag | Arylsulfonamido-substituted hydroxamic acids as matrix metalloproteinase inhibitors |
WO1996027583A1 (en) * | 1995-03-08 | 1996-09-12 | Pfizer Inc. | Arylsulfonylamino hydroxamic acid derivatives |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE212619T1 (de) * | 1996-10-22 | 2002-02-15 | Upjohn Co | Alpha-amino sulfonyl hydroxamsäure als matrix metalloproteinase inhibitoren |
ES2190115T3 (es) * | 1997-11-12 | 2003-07-16 | Darwin Discovery Ltd | Derivados de acido hidroxamico y carboxilico con actividad inhibidora de mmp y tnf. |
IL127496A0 (en) * | 1997-12-19 | 1999-10-28 | Pfizer Prod Inc | The use of MMP inhibitors for the treatment of ocular angiogenesis |
ES2220004T3 (es) * | 1998-04-10 | 2004-12-01 | Pfizer Products Inc. | Derivados del acido ciclobutil-ariloxiarilsulfonilaminohidroxamico. |
PA8469501A1 (es) * | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
-
1998
- 1998-01-12 PL PL98335027A patent/PL335027A1/xx unknown
- 1998-01-12 TR TR1999/01849T patent/TR199901849T2/xx unknown
- 1998-01-12 ID IDW990788A patent/ID22799A/id unknown
- 1998-01-12 KR KR1019997006971A patent/KR100317146B1/ko not_active IP Right Cessation
- 1998-01-12 SK SK1012-99A patent/SK283963B6/sk unknown
- 1998-01-12 HU HU0000852A patent/HUP0000852A2/hu unknown
- 1998-01-12 NZ NZ336840A patent/NZ336840A/en unknown
- 1998-01-12 EA EA199900604A patent/EA002594B1/ru not_active IP Right Cessation
- 1998-01-12 PT PT98900021T patent/PT977733E/pt unknown
- 1998-01-12 ES ES98900021T patent/ES2202796T3/es not_active Expired - Lifetime
- 1998-01-12 BR BR9807815-1A patent/BR9807815A/pt not_active Application Discontinuation
- 1998-01-12 DE DE69817801T patent/DE69817801T2/de not_active Expired - Fee Related
- 1998-01-12 DK DK98900021T patent/DK0977733T3/da active
- 1998-01-12 JP JP53266698A patent/JP3765584B2/ja not_active Expired - Fee Related
- 1998-01-12 EP EP98900021A patent/EP0977733B1/en not_active Expired - Lifetime
- 1998-01-12 WO PCT/IB1998/000023 patent/WO1998033768A1/en not_active Application Discontinuation
- 1998-01-12 AU AU81917/98A patent/AU721748B2/en not_active Ceased
- 1998-01-12 CA CA002279276A patent/CA2279276C/en not_active Expired - Fee Related
- 1998-01-12 IL IL13104298A patent/IL131042A/en not_active IP Right Cessation
- 1998-01-12 IL IL13014298A patent/IL131042A0/xx active IP Right Grant
- 1998-01-12 US US09/355,163 patent/US6303636B1/en not_active Expired - Fee Related
- 1998-01-12 CN CN98802991A patent/CN1113862C/zh not_active Expired - Fee Related
- 1998-01-12 AT AT98900021T patent/ATE248812T1/de not_active IP Right Cessation
- 1998-01-15 HN HN1998000011A patent/HN1998000011A/es unknown
- 1998-01-26 MY MYPI98000357A patent/MY121754A/en unknown
- 1998-01-29 PA PA19988445801A patent/PA8445801A1/es unknown
- 1998-01-29 AP APAP/P/1998/001191A patent/AP826A/en active
- 1998-01-30 UY UY24866A patent/UY24866A1/es not_active IP Right Cessation
- 1998-01-30 GT GT199800025A patent/GT199800025A/es unknown
- 1998-02-02 ZA ZA9800823A patent/ZA98823B/xx unknown
- 1998-02-02 MA MA24951A patent/MA26471A1/fr unknown
- 1998-02-02 TW TW087101196A patent/TW509668B/zh not_active IP Right Cessation
- 1998-02-02 DZ DZ980020A patent/DZ2410A1/xx active
- 1998-02-02 CO CO98004906A patent/CO4920234A1/es unknown
- 1998-02-02 AR ARP980100453A patent/AR011101A1/es unknown
- 1998-02-02 PE PE1998000069A patent/PE57799A1/es not_active Application Discontinuation
- 1998-02-02 TN TNTNSN98019A patent/TNSN98019A1/fr unknown
- 1998-02-03 HR HR980058A patent/HRP980058B1/xx not_active IP Right Cessation
- 1998-12-01 UA UA99084432A patent/UA63935C2/uk unknown
-
1999
- 1999-07-23 IS IS5129A patent/IS1950B/is unknown
- 1999-07-29 BG BG103616A patent/BG64308B1/bg unknown
- 1999-07-30 OA OA9900168A patent/OA11081A/en unknown
- 1999-08-02 NO NO19993730A patent/NO313631B1/no not_active IP Right Cessation
-
2000
- 2000-09-24 HK HK00105541A patent/HK1026203A1/xx not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5455258A (en) * | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
WO1996000214A1 (en) * | 1994-06-24 | 1996-01-04 | Ciba-Geigy Ag | Arylsulfonamido-substituted hydroxamic acids as matrix metalloproteinase inhibitors |
WO1996027583A1 (en) * | 1995-03-08 | 1996-09-12 | Pfizer Inc. | Arylsulfonylamino hydroxamic acid derivatives |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1113862C (zh) | 芳基磺酰氨基异羟肟酸衍生物 | |
CN1123566C (zh) | 芳基磺酰基异羟肟酸衍生物 | |
CN1171866C (zh) | 芳氧基芳基磺酰氨基异羟肟酸衍生物 | |
CN1225639A (zh) | 基于次膦酸酯的基质金属蛋白酶抑制剂 | |
JP4443037B2 (ja) | ペプチド含有α−ケトアミドのシステインおよびセリンプロテアーゼ阻害剤 | |
CN1192219A (zh) | 可逆的半胱氨酸蛋白酶抑制剂 | |
CN1504462A (zh) | 作为白细胞介素抑制剂的嘧啶基衍生物 | |
CN1305473A (zh) | 抑制整联蛋白与其受体结合的n,n-二取代的酰胺 | |
KR20000068248A (ko) | 아릴설포닐아미노 하이드록삼산 유도체 | |
CN1296481A (zh) | (4-芳基磺酰氨基)-四氢吡喃-4-羧酸羟基酰胺 | |
CN1198096A (zh) | 用于治疗与胶原蛋白过量产生有关的疾病的c-蛋白酶抑制剂 | |
CN1176080C (zh) | 茚并一,萘并一和苯并环庚二氢噻唑衍生物,它们的制备以及它们作为降低食欲药的用途 | |
CN1219166A (zh) | 联苯基磺酰胺基质金属蛋白酶抑制剂 | |
CN1202895A (zh) | 含咪唑取代基的巯基烷基肽基化合物及其用作基质金属蛋白酶(mmp)和/或肿瘤坏死因子(tnf“抑制剂” | |
CN1294578A (zh) | 新的萘基和酰苯胺取代的磺酰胺 | |
US6686335B1 (en) | Hydroxamate-containing cysteine and serine protease inhibitors | |
CN1555372A (zh) | 作为ace和nep抑制剂的吡喃衍生物 | |
CN1139572C (zh) | Nmda(n-甲基-d-天冬氨酸)拮抗剂 | |
US20020006920A1 (en) | Arylsulfonylamino hydroxamic acid derivatives | |
CN1166632C (zh) | 新的异羟肟酸化合物及其制备方法和含有它们的药物组合物 | |
CN1259940A (zh) | 晶体Roxifiban | |
WO1997010231A1 (en) | Ketomethylene group-containing cysteine and serine protease inhibitors | |
CN1059901A (zh) | 钙摄入抑制剂 | |
CN1127513C (zh) | 具有金属肽酶抑制活性的膦酸衍生物 | |
US6329377B1 (en) | Ketomethylene group-containing cysteine and serine protease inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
C10 | Entry into substantive examination | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |